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Normal Glycolytic Enzyme Activity is Critical for Hypoxia Inducible Factor-1α Activity and
Provides Novel Targets for Inhibiting Tumor Growth

By Geoffrey Grandjean
Advisory Professor: Garth Powis, D. Phil

Unique to proliferating cancer cells is the observation that their increased need for energy is
provided by a high rate of glycolysis followed by lactic acid fermentation in a process known as
the Warburg Effect, a process many times less efficient than oxidative phosphorylation
employed by normal cells to satisfy a similar energy demand

[1]

. This high rate of glycolysis

occurs regardless of the concentration of oxygen in the cell and is typically at rates significantly
higher than those found in normal cells of the same tissue type. Unlike the case of proliferating
cancer cells in culture, the internal environment of most solid tumors is hypoxic due to an
inadequate or disorganized blood supply leading to even greater increases in glycolytic rates
and, therefore, lactic acid production

[2]

. The regulation of glycolytic enzyme expression by the

hypoxia-inducible factor 1 alpha (HIF-1α) transcription factor in states of low oxygen stress is a
well described phenomenon

[3, 4]

. Through the use of a high throughput siRNA screen using an

siRNA library targeting all the known open reading frames of the human genome (Dharmacon,
Inc.), novel regulators of HIF-1α were identified including many enzymes involved in the
glycolytic pathway. Here, I describe a novel relationship between glycolysis and its regulation of
HIF-1α activity. Our studies have shown that of the 40 enzymes of glycolysis involving 11
enzymatic steps and various enzyme isoforms, siRNA knockdown of Aldolase A (ALDOA)
produces the maximum inhibition of HIF-1α activity in vitro – a finding that I have subsequently
confirmed in a murine in vivo model. Further study indicated that this is mediated through a
mechanism involving AMPK, a sensor of low ATP levels, and the subsequent dissociation of
HIF-1α and p300, a critical co-activator of HIF-1α. ALDOA was chosen as the molecular target
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for a drug discovery effort because it produced maximum inhibition of cancer growth and would
serve as a dual glycolysis and HIF-1α inhibitor, thus blocking two important cancer cell survival
mechanisms at the same time.
Tumor hypoxia is a pervasive problem in regards to treatment options as hypoxic tumor cells
are resistant to traditional chemo and radiotherapies.

Thus, the overreaching goal of this

research is to identify viable dual inhibitors of energy production and specific stress survival
pathways to be used as a combinatorial therapy for patients in which tumor hypoxia has
rendered standard therapeutic tools ineffective.
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Introduction
The targeted, preferential killing of cancer cells without non-specific toxicity to normal cells in
the body is one of the most critical and difficult challenges in cancer chemotherapy. In order to
create effective, non-toxic anticancer agents it is essential to gain a comprehensive
understanding about the biological and biochemical processes that differ between these
cancerous and normal cell populations. As technology and laboratory techniques have evolved
over the years, tremendous progress has been achieved in the understanding of signaling
molecules, specific genes, and proteins that are involved in cancer development and
progression and with this progress has come a better appreciation for the need for these
targeted therapies. With every discovery, however, comes a greater understanding about the
complexities inherent to this disease. The high level of heterogeneity commonly found among
the cells of a single tumor serves as a confounder as the wide range of genetic and epigenetic
alterations can be so diverse that often the use of a single agent is impossible. For this reason,
a range of target specific agents is often used in a cocktail of therapies to eliminate a wider
range of malignant cells. Alternatively, the identification and subsequent exploitation of a
fundamental difference between normal and cancer cells could lead to a level of therapeutic
selectivity not previously described by allowing for remedial discrimination between malignant
cells and those associated with a patient’s healthy tissue.

Glycolysis and Cancer
Aerobic glycolysis occurs by the Embden-Myerhoff-Parnas pathway, a series of cytoplasmic
enzymatic steps converting glucose to pyruvate (generating 2 ATP per molecule of glucose).
Pyruvate is metabolized by the mitochondrial tricarboxylic acid (TCA) cycle generating NADH,
which fuels oxidative phosphorylation (thus producing 36 ATP for one molecule of glucose). In
the first phase of glycolysis, molecular glucose undergoes a series of phosphorylations and
isomerizations in preparation for its cleavage into two triose molecules. In the second phase of
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glycolysis, glyceraldehyde 3-phosphate undergoes a series of energy-releasing processes to
not only recover ATP that is invested early in the glycolytic process, thus providing chemical
motive for further execution of the cascade, but also the generation of ATP through substratelevel phosphorylation

[5]

(Figure 1). Cancer cells rely heavily on glycolysis and, under aerobic

conditions, it can provide over 60% of the cancer cells’ ATP compared to just 10% in normal
cells. Warburg attributed this effect to defective mitochondrial oxidative phosphorylation in
cancer cells

[6]

, but subsequently it was shown that cancer cells have normal oxidative

phosphorylation

[2, 5, 7, 8]

. More recently it has been shown that many actively dividing cells have

high rates of glycolysis, and in most cases neither ATP nor NADH is limiting for cell growth

[2]

. It

is now recognized that glycolysis is also a critical source of metabolic intermediates for the rapid
synthesis of amino acids, nucleosides and lipids of the cellular biomass. High levels of aerobic
glycolysis have been measured in a wide range of tumor types regardless of the tissue type
from which they originated, as compared to their normal tissue counterparts which do not utilize
aerobic glycolysis to satisfy their energy demands. This suggests that a characteristic of cancer
cells, in combination with unrestrained growth, is that they revert to a metabolic phenotype,
namely increased glycolysis, which provides proliferative advantages to rapidly dividing cells.
This increased glycolysis in cancer cells is commonly referred to as the Warburg effect.
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Figure 1. The Glycolysis/HIF-1 Feed Forward Cycle in Cancer.
In upper glycolysis glucose is phosphorylated and isomerized to enable its cleavage into two trioses:
1 – Glucose is phosphorylated at the 6 carbon through the use of ATP by the transferase class enzyme Hexokinase.
This regulatory step is negatively regulated by the accumulation of the product, glucose-6-phosphate.
2 – Glucose-6-phosphate is then converted to Fructose-6-phosphate (F-6-P) by Phosphoglucoisomerase
3 – Fructose-6-phosphate is phosphorylated at the 1 carbon position, again through the use of ATP, by the
transferase class enzyme Phosphofructokinase to yield Fructose-1,6,bisphosphate (FBP). This is often considered
the primary control step in glycolysis as it is the committed step of the process due to its large delta G value.
4 – FBP is then cleaved into two, three carbon molecules – Dihydroxyacetone phosphate (DHAP) and
Glyceraldehyde-3-phosphate – by the lyase class enzyme Aldolase (Aldolase A [ALDOA]) is our primary
target for inhibition shown in red).
5 – DHAP produced in step 4 is converted to Glyceraldehyde-3-phosphate by Triose phosphate isomerase to satisfy
the needs of the first step of lower glycolysis.
In lower glycolysis, glyceraldehyde 3-phosphate undergoes two major energy-releasing electron rearrangements.
6 – Glyceraldehyde-3-phosphate is phosphorylated at the 1 carbon position by Glyceraldehyde-3-phosphate
dehydrogenase to yield 1,3-Bisphosoglycerate (BPG).
7 – Phosphoglycerate kinase phosphorylates ADP to yield ATP and 3-phosphoglycerate (3-PG).
8 – 3-PG is converted to 2-phosophoglycerate by Phosphoglycerate mutase.
9 – 2-phosphoglycerate is then converted to phosphoenolpyruvate (PEP) by Enolase. H2O, potassium and
magnesium are all released as a result.
10 – Pyruvate kinase uses PEP to phosphorylate ADP and yield pyruvate. High levels of ATP, Acetyl-CoA, Alanine
and cAMP can all negatively regulate this step.
In parenthesis are number of isoenzymes, * indicates proteins induced by HIF-1.
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Anaerobic Glycolysis
In conditions of limited oxygen as found in most solid tumors (<1% O2 compared to 3–15%
O2 found in normal tissues), pyruvate is converted to lactate by a process known as anaerobic
glycolysis, and the lactate is then mostly secreted from the cell, although recent work suggests
that in the heterogeneous tumor environment, some cells can use lactate as a source of fuel for
mitochondrial oxidative phosphorylation

[9]

. There are 11 enzymatic steps to glycolysis with 40

possible contributing isoenzymes. Glycolysis has to be supplemented by an increase in cellular
glucose uptake through GLUT transporters that are also upregulated in cancer
18

the basis for

[10, 11]

, forming

F-deoxyglucose positron emission tomography (FDG-PET) measurement of

glucose uptake by patient tumors as an indicator of response to therapy

[12, 13]

. Activation of

oncogenes, or loss of tumor suppressors can lead to upregulated glycolysis and glucose
transport in cancer. These include PI-3-kinase, oncogenic protein tyrosine kinases that act
through PI-3-kinase, and loss of the tumor suppressor PTEN, that all lead to downstream
activation of AKT that maintains hexokinase function and localizes glucose transporters to the
cell surface

[14, 15]

mutant KRAS

. Myc activates the transcription of several glycolytic enzymes

[18, 19]

[1, 16, 17]

as does

. Inactivation of the tumor suppressor p53 causes a shift of energy

metabolism to glycolysis through down regulation of mitochondrial respiration as a result of
cytochrome C oxidase (COX) deficiency [20].

Tumor Hypoxia as an Inducer of Glycolysis
Hypoxic regions present in all solid tumors occur due to decreased blood flow and
disorganized tumor vasculature and provide a stressful environment favoring tumor growth [21-23].
A cancer cell’s response to hypoxia is mediated by the hypoxia inducible transcription factors
HIF-1 and 2

[24, 25]

, which together increase expression of numerous survival genes. Among

them are genes that encode vascular endothelial growth factor (VEGF) (by HIF -1 and HIF-2
28]

), glycolytic enzymes (by HIF-1 only

[29]

[26-

) and induction of the expression of GLUT-1 glucose
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transporter

[10, 17]

. At the same time there is inhibition of mitochondrial aerobic respiration

through induction of pyruvate-dehydrogenase kinase-1 (PDK1)

[30]

. Additionally, it has been

shown that the ability of mutant KRAS, found in more than 97% of pancreatic cancer, to
increase glycolysis is mediated through expression of HIF-1α, which is detectable in pancreatic
cancer cell lines even under aerobic conditions [18, 19, 31].

Inhibitors of glycolysis as cancer drugs
A number of attempts have been made to develop inhibitors of enzymes of glycolysis as
potential anticancer agents

[32-37]

. These have typically been simple small molecule analogs of

substrates of glycolytic enzymes and include 2-deoxyglucose a competitive inhibitor of glucose
utilization

[38, 39]

which has, historically, shown minimal clinical activity at doses that can be safely

administered to patients
[41, 42]

PDK1

[40]

, 5-thioglucose and 3-bromopyruvate as hexokinase (HK) inhibitors

when infused in rabbits are severely hepatotoxic
[44]

[43]

, and dichloroacetate, an inhibitor of

which is known to cause toxic neuropathy in humans

[45]

. Overall the use of small

molecule substrate analogs to inhibit glycolysis has yielded disappointing clinical effects, and in
many cases considerable toxicity.

HIF-1 as a Tumor Survival Factor and Cancer Drug Target
HIF-1 and 2 are critical mediators of the hypoxic response and transactivate a large number
of genes promoting a wide range of factors associated with cancer progression including
angiogenesis, anaerobic metabolism and resistance to apoptosis
inducing glycolytic enzyme genes

[24, 29]

[46]

with HIF-1α preferentially

. HIF-1 is a heterodimer comprised of an oxygen labile

HIF-α subunit and a stable HIF-1β subunit. Under aerobic conditions HIF-1α is hydroxylated by
the prolyl hydroxylase proteins and subsequently ubiquitinated by the von Hippel Lindau protein
(pVHL) and targeted for proteasomal degradation

[47]

. During hypoxia, pVHL binding is
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abrogated due to the lack of this hydroxylation. The resulting stabilization of HIF-1α causes its
translocation to the nucleus where it heterodimerizes with HIF-1β and binds to a conserved
DNA sequence known as the hypoxia responsive element (HRE), thus transactivating a variety
of hypoxia-responsive genes

[48]

. Elevated levels of tumor HIF-1α have been associated with

poor patient survival in multiple tumor types

[49]

. HIF-1α is thus an attractive target for cancer

drug development and a number of inhibitors have been reported [50]. Recently the clinical trial of
a first generation HIF-1α inhibitor, PX-478 was reported with promising results establishing the
validity of HIF-1α as a drug target

[51]

. The mechanism by which PX-478 inhibits HIF-1α remains

unclear and the off target side effects of PX-478 will likely limit its future development. However,
HIF-1α remains a promising target for drug development and second-generation inhibitors with
defined mechanisms of action and low toxicity are needed.

ALDOA as a Cancer Drug Target
It is known that malignant transformation results in a significant change in the expression of
glycolytic isoenzymes and favors those isoenzymes that facilitate survival and uncontrolled
proliferation. It has been found that the expression of ALDOA is significantly elevated relative to
the two other isoforms, ALDOB and ALDOC, in a wide variety of human tumor types including
pancreatic cancer

[29]

. ALDOA is also highly expressed in developing embryos suggesting it is

adapted to the metabolic requirements of rapid cell proliferation

[52, 53]

. ALDOA has also been

shown to have a kcat that is significantly higher than that of the other ALDO isoenzymes

[54, 55]

.

Based on these findings it has been suggested that ALDOA could serve as a cancer drug target
for inhibiting glycolysis

[33, 56]

. We have now shown a novel finding that ALDOA is the most

important of the 40 isoenzymes of glycolysis responsible for maintaining HIF-1 activity. It is a
doubly attractive target based on the finding that its inhibition leads to both an inherent reduction
in cancer cell energy metabolism and HIF-1 activity. Aldolases have also been reported to bind
to a number of non-glycolytic proteins including F-actin

[57]

, WASP and N-WASP, activators of
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Arp2/3 and actin polymerization

[58]

and the PH domain of phospholipase D2

[59]

. Although the

significance of this binding is not clear, the observations have also led to the suggestion that
Aldolases could be a target for inhibiting cancer growth [60].
Summary
In this study, the identification of a novel feed-forward cycle of increased HIF-1α and
increased glycolysis that is critical for tumor growth and survival, is paired with an understanding
that the inhibition of the glycolysis/HIF-1 cycle is selective for hypoxic tumor cells due to the fact
that normal aerobic dividing cells, despite using aerobic glycolysis do not express HIF-1.
Inhibiting this cycle, thus, provides a novel way to target human malignancies. In pancreatic
cancer where the glycolysis/HIF-1 cycle appears to be particularly prominent, the key activating
event may be increased HIF-1α by mut-KRAS even in hypoxic conditions. This may be why
KRAS signaling is significantly correlated with glycolysis in pancreatic cancer

[61, 62]

. Considering

this fact and taking into account that it is overexpressed in pancreatic cancer and strongly
associated with decreased patient survival, we have identified and validated the glycolysis
enzyme ALDOA as a critical step in the glycolysis/HIF-1 cycle. By using ALDOA as a target for
the design of pharmacological probes, we are able to attack, at the same time with a single
agent, two critical cancer survival mechanisms: glycolysis and angiogenesis. ALDOA has a
known crystal structure which allowed us to use molecular modeling for lead optimization, and
co-crystallography for validation of ALDOA-inhibitor leads. Through the combination of virtual
screening, high-throughput consideration of large small molecule libraries and subsequent
validation of lead compounds in biological assays, we have identified low micromolar affinity
inhibitors of ALDOA as tool compounds and as potential leads for preclinical development as
novel anticancer agents. Further, we have identified a potential mechanism for inhibition of
ALDOA leading to decreased HIF-1 activity through the AMPK inhibition of the HIF-1 coactivator p-300 allowing for the combination of novel target identification, elucidation of
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biological mechanisms responsible for the critical nature of the target in the progression of
human cancer, discovery of probe inhibitors and validation of their efficacy using both in vitro
biochemical and in vivo anti-tumor experiments.

Materials and Methods
Cells and Culture Conditions
MIA PaCa-2, MDA-MB-231, and PANC1 cell lines were obtained from the American Type
Culture Collection (ATCC) and grown in DMEM media; HT-29 cells were obtained from ATCC
and cultured in McCoy’s 5A media. DNA fingerprinting was conducted by the University of
Texas M.D. Anderson Cancer Center Characterized Cell Line Core Service at the same time as
total protein lysate preparation in order to confirm the identities of cells used in all experiments.
All cell lines were routinely tested to be mycoplasma free using the e-Myco kit (Boca Scientific).

Creation of Stable and Inducible Cell Lines
Following karyotype analysis, a 5X HRE repeat (hypoxia response element) sequence from
the VEGF and EPO genes was cloned in front of firefly luciferase in the pGL3 Basic Vector. This
HRE/luciferase sequence was then sub-cloned into the pcDNA3.1 vector with Neomycin
resistance. The resulting plasmid was transfected into MIA PaCa-2 and PANC1 pancreatic
carcinoma, MDA-MB-231 breast adenocarcinoma, and HT-29 colorectal adenocarcinoma cells
and stable clones selected following long term culture in DMEM 10% FBS with G418 selective
pressure using 300 µg/mL Geneticin (Invitrogen).The reporter plasmid was a gift of Dr. R. Gillies
(Moffitt Cancer Center, Tampa, FL). Following selection, pools of stably transfected cells were
generated and frozen for later use.
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For conditional Aldolase A knockdown in an in vivo murine model, four sequences predicted
to target ALDOA gene expression were selected from the Thermo Scientific Dharmacon shRNA
library and each was inserted into a TRIPZ doxycycline inducible lentiviral vector (Open
Biosystems). Each of the four HRE luciferase lines described above was transduced with
shALDOA-expressing lentivirus, and stable lines were selected in puromycin in 96-well plates
with one cell per well to generate clonal populations. After puromycin and G418-resistant clones
were selected, shALDOA expression was induced using doxycycline in both normoxia and
hypoxia (1% O2) to assess ALDOA knockdown.

siRNA Screening
Cells underwent two consecutive passages in the absence of G418 selection before
confirmation that the cells were mycoplasma negative. Optimization of ideal transfection reagent
and reagent concentration was carried out using high-throughput optimization methods for
reverse transfection (Figure 2). In the course of this process, 8 transfection reagents from
various manufacturers (DharmaFECT 1, 2, 3, and 4 [Dharmacon], XtremeGENE [Roche],
Lipofectamine RNAiMAX [Invitrogen], HiPerfect [Qiagen], or siPort NeoFX [Thermo Fisher
Scientific]) were used in a range of concentrations per well and paired with one of nine negative
(siGenome Scrambled Non-targeting control 1, 2, 3, 4 or 5 or siOnTargetPlus Non-targeting
control 1, 2, 3, or 4 [Dharmacon]) or one of four positive controls (siPLK1 an inhibitor of the
G2/M transition

[63]

, siTOX an inducer of the interferon response

Golgi budding and vesicular trafficking
[66]

[65]

[64]

, siCOPB2 an inhibitor of

, or siKIF11 an inhibitor of mitotic spindle formation

). Optimal combinations were identified by calculation of z’-factor ultimately yielding the

combination of least toxic and most efficient transfection reagent, least toxic negative control
siRNA and most effective positive control siRNA per cell line.
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Figure 2. siRNA Transfection Optimization Format
The combination of 8 transfection reagents with nine positive and four negative control siRNAs allows for the
identification of the optimal combination of reagents and controls per cell line when the z’-factor criteria was satisfied
per the following equation:
Z’-factor = 1-(3*(SSD/(Range)))
SSD – sum of standard deviations in negative control and positive controls samples
Range – negative control average – positive control average

If the end value was greater than .7, the assay was considered robust enough to continue.
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Following optimization, parallel screens were then carried out with a genome wide siRNA
library (Dharmacon) in one of two different levels of oxygenation: normoxia or hypoxia.
Optimization of cell number and O2 level was conducted in order to identify the ideal conditions
for hypoxia related experiments (Figure 3). To this end, 60–70% confluent cells were cultured
in a hypoxia chamber (InVIVO2 400, Ruskinn) flushed with 1% O2 and 5% CO2 with balance of
94% nitrogen at 37  °C for 16 hours following 48 hours of transfection in air. Control cells were
placed in a 5% CO2 and 95% air incubator (20% O2) at 37  °C for the duration of the experiment.
All experiments were conducted in 384 well, white, clear-bottom, tissue culture treated plates
(Falcon) in which 10 µl of 1x siRNA buffer containing 200 nM siRNA was complexed with 10 µl
of OptiMEM transfection media containing 0.07 µl of XtremeGENE (Roche) for 30 minutes prior
to the addition of a mixture of 30 µl of complete DMEM media (10% FBS) and 2000 cells. At the
completion of experiments, cell viability was first measured using the cell proliferation reagent
WST-1 (Roche) followed by the washing of the wells with PBS and subsequent analysis of
HRE-luciferase expression and activity using an in-house luciferase assay buffer containing 25
mM Tricine, 0.5 mM EDTA-Na2, 0.54 mM Na-triphosphate, 16.3 mM MgSO4*7 H2O, 0.3%
Triton X-100, 0.1% DTT, 10 mM ATP, and 2.7 mM Coenzyme A adjusted to pH 7.8 to yield a
combined viability and HRE activity reading.
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Figure 3. Optimization of O2 Conditions Based on Growth Rate and HRE-luciferase Activity in Hypoxia Based
Experiments
Growth rate (based on cell number) and HRE-luciferase activity was measured at 12 hour time points in order to
identify optimal oxygen concentration conditions and duration of the exposure to hypoxia in order to have the highest
possible baseline HRE-activity during the high throughput siRNA screen to find inhibitors of HIF-1 transcriptional
activity. Values are the mean of 6 determinations. Bars are S.D.
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Individual siRNA Transfection
After identifying initial glycolysis genetic hits, follow-up work in each of the 3 additional cell
lines listed was conducted by de-convoluting pooled siRNA for selected targets from an
alternative supplier for additional validation purposes. For transfection in a six well plate format,
300 µl of 1x siRNA buffer containing 200 nM siRNA was added to each well followed by 300 µl
of OptiMEM with 2.5 µl of either DharmaFECT 4 (for MDA-MB-231 and PANC1 transfections),
DharmaFECT 1 (for HT-29) or XtremeGENE (for MIA PaCa-2). Following 30 minutes of
incubation at room temperature to allow for transfection reagent-siRNA complexing, 900 µl of
complete media containing 100,000 cells was added per well yielding a final screening
concentration of 40 nM siRNA. Per well siALDOA SMARTpool (Dharmacon, M-010376-01),
individual siALDOA siRNAs (Qiagen GS226), siPGK1 SMARTpool (Dharmacon, M-006767-01),
individual siPGK1 siRNAs (Qiagen, GS5230), siPGK2 SMARTpool (Dharmacon, M-006768-02),
or individual siPGK2 siRNAs (Qiagen, GS5232) was added and knockdown efficiency was
determined by Western blotting of cell lysates 96 hours post transfection. Dharmacon
SMARTpool siRNAs for HIF-1α, AMPK, EP300, PLK-1 or the On-Target-Plus non-targeting pool
#4 (OTP4) were included as controls. Total siRNA concentration was kept at 40 nM when
siRNA combinations were used.

Immunoblots and Immunoprecipitations
Cells were washed twice with pre-chilled, ice-cold PBS before adding ice-cold lysis buffer
containing 50 mmol/L HEPES (pH 7.5), 50 mmol/L NaCl, 0.2 mmol/L NaF, 0.2 mmol/L sodium
orthovanadate, 1 mmol/L phenylmethylsulfonyl fluoride, 20 µg/mL aprotinin, 20 µg/mL leupeptin,
1% NP40, and 0.25% sodium deoxycholate. Following scraping, samples were vortexed
frequently on ice for 20 minutes, followed by microcentrifugation at 14,000 rpm for 10 minutes.
Cleared supernatants were collected, followed by protein quantification using the BCA reaction
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kit (Pierce Biotechnology, Inc.) and 50 µg of cell lysate protein were boiled for 5 min with
denaturing buffer containing 0.25 mol/L Tris (pH 6.8), 35% glycerol, 8% SDS, and 10% 2mercaptoethanol, loaded on a 10% acrylamide/bisacrylamide gel, and separated by
electrophoresis at 90 V for 1 hour and 20 minutes. Proteins were electrophoretically transferred
to a methanol activated polyvinylidene fluoride (PVDF) membrane; pre-incubated with a
blocking buffer of 5% milk; and incubated overnight with anti–phosphorylated Thr172 – AMPK or
anti-AMPK (Cell Signaling 1:1000), anti-HIF-1α (BD Biosciences 1:500), anti-Aldolase A
(AbNova 1:500), anti-Aldolase B or anti-Aldolase C (Novus Biologicals 1:1000), antiphosphorylated Ser89-EP300 or anti-EP300 (Santa Cruz Biotechnology 1:1000) or anti-β-actin
(Santa Cruz Biotechnology 1:2000). Donkey anti-rabbit, sheep anti-mouse (GE Healthcare), or
donkey anti-goat (Santa Cruz Biotechnology) IgG horseradish peroxidase-coupled secondary
antibody was used for detection where appropriate. Band density was measured using the
densitometry functionality found within the Image-J open source image analysis program
following ECL mediated image development on either Kodak X-Omat Blue ML films (Eastman
Kodak) or the FluorChem M Imaging Platform (Protein Simple).

Determination of Cellular ATP Concentration
Cellular ATP was measured using an ATP Assay Kit (Abcam) according to the
manufacturer’s protocol and quantified by both colorimetric (λmax = 570 nm) and fluorometric
(Ex/Em = 535/587 nm) methods, 96 hours post siRNA-transfection. Each experiment was
performed in both biological and technical triplicates.

Xenograft Analysis
Approximately 107 MDA-MB-231 HRE cells, MDA-MB-231 cells harboring shALDOA clones
8.8 and 9.7, and MDA-MB-231 HRE empty vector cells, all in log cell growth, were suspended
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each in 0.2 mL PBS and injected subcutaneously into the mammary fat pads of female NODSCID mice. Groups contained five mice each. When the tumors reached 250 mm3, chow
containing doxycycline was substituted for control feed (Harlan Laboratories) in test groups. An
additional group of five mice was fed doxycycline containing chow for one week prior to injection
of the inducible cells to measure the possible inhibitory effect on initial tumorigenesis. Mice
were euthanized when they became clinically moribund associated with the metastatic spread of
the MDA-MB-231 tumor to liver and lung. Animal studies were approved by SBPMRI’s Animal
Care and Use Committee.

Molecular modeling
Target Receptor and Chemical Database selection
The crystal structure of Aldolase was obtained from the Protein Data Bank
considered as the basis for virtual screening

[68]

[67]

(4ALD) and

. For the ligand set used in these virtual screens,

we selected the 10,000 compound Myria Screen chemical library.

Virtual Screening
The virtual screens were performed using the GOLD (Genetic Optimization for Ligand
Docking) software from CCDC

[69]

. GoldScore was chosen as the fitness function, and 29

residues within 6Å of 2FP (fructose 1,6-bisphosphate) were selected as defining the binding
site.
Two successive GOLD screens were carried out: the first screen docked the entire
MyriaScreen ligand set into a rigid structure in which no considerations were made as to
flexibility of the structure. The resulting top 2000 ligands were then clustered based on structural
MACCS (Molecular ACCess System) fingerprints using MOE fingerprint clustering. The second
screen considered only the top 60 unique scoring ligands allowing for flexible side chains. Using
the Tanimoto coefficient with chemical similarity and overlap considerations set to 60%, cluster

15

centers were retained. The resulting 60 unique ligands from this clustering were then minimized
in MOE, and screened a second time in GOLD with full flexibility considerations made for the
following Aldolase residues: Asp33, Ser38, Lys146, Arg148, Glu187, and Lys229. These
residues were selected as flexible based on location relative to the binding site and propensity
to form favorable interactions with the natural substrate, 2FP.
The results from the second screen were then individually visualized (using PyMOL) in their
docked conformation (protein-ligand complex). Two main criterions were considered in the final
selection process. First was the resulting orientation and configuration within the protein
structure. We considered interactions that would increase the binding affinity (e.g. hydrogen
bonds, static and aromatic effects). The second consideration was the distinctiveness in the
molecular scaffold when compared to the other ligands at this stage. We placed the ligands into
“classes” based upon the individuality of their underlying scaffold and how this scaffold was
oriented in the binding site. Ligands that shared a similar scaffold and orientation were
considered to be in the same class. Based on the combination of the two criteria, 22 ligands in
total were recommended to be tested for biological activity.

Aldolase Enzymatic Activity Assay
A 96 well plate assay based on conversion of fructose 1,6-bisphosphate (F-1,6-BP) into
glyceraldehyde 3-phosphate (GAP) and dihydroxyacetone phosphate (DHAP) measured in a
coupled reaction with GAP dehydrogenase by the oxidation of NADH to NAD was used to
measure the effect on Aldolase A cleavage activity using an adapted method previously
described [70]. All enzymatic assays were conducted at 22º C in a final volume of 100 µl following
the addition of recombinant Aldolase A protein (Novus Biologicals) to a reaction mixture
containing substrate, 0.15 mM NADH, 50 mM Tris-acetate, 10 mM EDTA (pH 7.6), 100 mg/ml
bovine serum albumin, and 2 mg/ml α-glycerophosphate dehydrogenase/triose phosphate
isomerase. Enzymatic activity was measured by endpoint assay at 364 nm sampling at 30
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second intervals. Initial attempts to verify ability of previously selected compounds from virtual
screening methods to inhibit Aldolase activity was monitored by following this NADH-dependent
coupled reaction at 340 nm proved to be incompatible with high throughput screening due to
spectroscopic interference at 340 nm by compounds typically found in screening collections. To
address this challenge we developed a robust fluorescence-based assay for ALDOA (Figure 4)
and screened a collection of >65,000 compounds (Table 1) in 384-well format, identifying
approximately 20 novel inhibitors with EC50‘s in the range of 1-20 µM, whose affinity compare
favorably to that of Fru-1,6-P2 using the protocol outlined in Figure 5.
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Abbreviations:	
  
ADL	
  (Aldolase)	
  
GDH	
  (Glycerophosphate	
  Dehydrogenase)	
  
F-‐1,6-‐DP	
  (Fructose-‐1,6-‐diphosphate)	
  
DAP	
  (Dihydroxyacetone	
  phosphate)	
  
GAP	
  (D-‐Glyceraldehyde-‐3-‐phosphate)	
  
GP	
  (L-‐a-‐Glycerol	
  phosphate) 	
  

Figure 4. Optimization of Fluorescence-based NADH Oxidation HTS Aldolase Assay
Glyceraldehyde-3-phosphate
dehydrogenase
converts
glyceraldehyde-3-phosphate
(G-3-P)
to
1,3bisphosphoglycerate (1,3-BGP) through oxidative phosphorylation. NAD+ is reduced to NADH when a phosphate
group is exchanged for a hydrogen on the carbonyl carbon of G-3-P thus converting G-3-P to 1,3-BGP. This assay
uses glycerophosphate dehydrogenase to catalyze the conversion of dihydroxyacetone phosphate (the product of the
ALDOA catalyzed reaction) to glyceraldehyde-3 phosphate in an NADH-dependent manner. Thus, the rate of change
of fluorescence intensity is used to indirectly calculate the activity of ALDOA.
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Compound Collection

Total
Compounds

# of Hits

Hit Rate

Kinase focused

652

14

2.15

NIH clinical

674

4

0.59

Lopac

1,280

4

0.31

Spectrum

2,000

15

0.75

Academic (UT Austin/Kansas)

2,100

7

0.33

NCI Diversity

2,537

12

0.47

Chembridge Fragment

4,000

69

1.73

Chembridge KINASet

11,250

94

0.84

Chemdiv Fragment

12,800

70

0.55

Chemdiv Diversity

14,243

132

0.93

Maybridge Diversity

14,400

219

1.52

Total

65,936

640

0.97

Table 1. Commercial and Academic Small Molecule Collections and Corresponding Hit Rates in High
Throughput Small Molecule Inhibitor Screen
Commercial and academic collections used in the high throughput small molecule inhibitor screen representing
structurally diverse sets of compounds known to be biologically active and drug like:

•
•
•
•
•
•
•

•
•

The kinase focused library was custom-selected by screening group at UT Austin and is comprised of 600+
compounds known to have inhibitory effects against more than 100 kinases.
The Evotec NIH clinical collection is part of the NIH Molecular Libraries Small Molecule Repository which
distributes samples for high throughput biological screening.
1280
Lopac
from Sigma-Aldrich is a collection of 1280 pharmacologically active compounds including
marketed drugs
The Spectrum collection uniquely offers a combination of drug components, natural products, and other
bioactive components which have been dropped from development for toxicological or other reasons.
Academic collections were a result of deposited samples composed of unique molecules with diverse
pharmacophores by chemists at both the University of Texas at Austin and University of Kansas.
The NCI diversity set is a small library, ideal for beginning a screening campaign, consisting of a collection
of chemically diverse synthetic small molecules selected from the full NCI screening collection to allow
users to focus their cancer screening efforts on a small scale.
The Chembridge Fragment and Kinase Sets are customizable collections of fragment compounds chosen
based on satisfaction of the Astex Rule of Three in which the compound’s molecular weight is <300, the
[71]
number of hydrogen bond donors is ≤3, the number of hydrogen bond acceptors is ≤3 and ClogP is ≤3
and in silico validated pharmacophores that may interact with ATP ligand sites of kinases.
Fragments in the Chemdiv collection contain only C, H, N, O, S, P, F, Cl and Br atoms, are highly water
soluble and feature diversity, low structural complexity and a high level of drug-likeness.
Additional diversity found in the Maybridge collection has a high rate (95%+) of satisfying Lipinski’s Rule of
5.

Hits were selected based on inhibition of Aldolase enzymatic activity by at least 30% relative to negative controls
using a modified Elite NADH fluorescent probe coupled enzymatic activity assay.
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Figure 5. High Throughput Small Molecule Screening Protocol:
1.

Prepare a 2x Aldolase A mixture (5 nM) in 1X assay buffer (1x PBS 0.01% TritonX-100, 0.1% BSA) and
dispense 4 µl to the assay plate (AP)
2. Spin plate at 800 RPM for 1 minute to ensure that entire volume is at the bottom of each well
3. Dispense 30 µl water into dilution plate (DP) and add 0.6 µl of 10 mM compound solutions to make a 200
µM (4x) compound stock solution.
4. Directly transfer 2 µl of the compound stock to the assay plate.
5. Spin plate at 800 RPM for 1 minute, seal, and incubate at room temperature for 1 hour.
6. Prepare 4x substrate mixture (F(1,6)BP, Glyceraldehyde Dehydrogenase and NADH) in 2x assay buffer.
7. Dispense 2 µl of substrate mixture into assay plate.
8. Spin plate at 800 RPM for 1 minute, seal, shake plates at 250 RPM for 5 minutes followed by an additional
800 RPM spin.
9. Incubate plates for 40 minutes at room temperature.
10. Mix NADH recycling enzyme with NADH assay buffer from the Elite NADH assay kit and dispense 8 µl into
assay plate.
11. Spin plate at 800 RPM for 1 minute, seal, and incubate for 1 hour at room temperature.
12. Read fluorescence intensity with excitation/emission spectra at 540/590 nm per the manufacturer’s
instructions.
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Measurement of Cellular Glycolysis
Glycolytic function was assessed by quantifying the rate of lactate formation using the
Seahorse Bioscience XF96e platform (Seahorse Bioscience) and the XF Glycolysis Stress Test
Assay according to the manufacturer’s protocol. Historic studies of cellular function have been
performed on monolayer cultures adherent to rigid substrates. Cells within a human tissue,
however, are typically encased within a tightly packed mass of cells in which connections with
many neighbors and with extracellular matrix components occur. Cells within a 3D environment
experience fundamentally different growth conditions compared to those experienced by cells
grown in monolayer culture. In order to measure glycolysis under hypoxic, physiologically
relevant conditions, a modified hanging drop tissue culture method

[72]

was used to evaluate 3-

dimensional spheroids of PANC-1 HRE cells transduced with shALDOA constructs. On the lid
of a 100 mm2 tissue culture dish, 20 10 µl droplets of complete media containing 10,000 +/2500 cells (depending on cell line) were arrayed using a multi-channel pipette. The bottom of
the dish was filled with 5 ml of PBS to act as a hydration chamber to prevent evaporation of
volume from the hanging drop during 3 day incubation times. Three days after seeding cells
and 24 hours before running the XF Glycolysis Stress Test, shALDOA expression was induced
with 400 ng/ml doxycycline. A final volume of 175 µl of pre-conditioned assay medium
containing 18 spheroids was added to each well of a test plate and incubated at 37ºC in a CO2free incubator until the experiment was initiated. The use of this hanging drop method allowed
for the generation of spheroids ranging in size from 300-500 µm which exhibited a hypoxic core
based on analysis with a fluorescent LOX-1 hypoxia probe (SCIVAX USA, Inc) without the need
for hypoxic gassing conditions.
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Crystallization and Structure Solution
Screens for the identification of optimized crystallization conditions were performed using a
96-reagent crystallization screen Index (Hampton Research) and a Phoenix robotic drop
dispenser (Art Robbins Instruments). Using the sitting drop vapor diffusion method, ALDOA was
co-crystallized with inhibitor naphthalene-2,6-diyl bis(dihydrogen phosphate) (NBP). Drops (0.4
µl each) containing 0.2 µl of the protein solution (18 mg/ml ALDOA, 3 mM NBP, 15 mM TRIS
buffer pH 7.6, 150 mM NaCl, 0.7 mM TCEP), and 0.2 µl of the crystallization buffer (25% PEG
3350, HEPES buffer pH 7.0), were equilibrated against the crystallization buffer at 23°C.
Crystals grew within 2 weeks measuring 0.20x0.06x0.06 mm3. To measure the binding capacity
of a lead compound found in high throughput screens of chemical libraries, a 4-benzyl-2-methyl1,2,4-thiadiazolidine-3,5-dione (TDZD-8) (MedKoo Biosciences) complex was made by soaking
preformed NBP co-crystals in PEG 3350 (23% w/v) containing 1.5 mM TDZD-8 for 4 h at 23°C.
Crystals were flash-frozen in liquid nitrogen after adding 15% PEG 400 as a cryoprotectant.
Diffraction data were collected at the Stanford Synchrotron Radiation Laboratory (SSRL),
beamline 12-2, and processed using AUTOXDS

[73]

and the CCP4i program suite

structures were solved using the molecular replacement program PHASER

[75]

[74]

. The

and the ALDOA

structure (PDB ID: 1ALD) as the search model. Refinement and manual rebuilding were done
with REFMAC5

[76]

and COOT

[77]

. The final model is refined at 2.5 Å resolution to an R-factor of

20% (RFREE = 24%).

The Cancer Genome Atlas Data Analysis
Comparison of tumor and paired normal tissue samples from 9755 patients for ALDOA,
ALDOB and ALDOC mRNA in The Cancer Genome Atlas (TCGA) PANCAN datasets was
carried out using publicly available data. Survival data was corrected for tumor type, patient age
and patient sex. In this way, TCGA data for mRNA expression as it relates to patient survival
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was used to analyze differences between paired samples using the student’s t-test in addition to
calculation of Pearson’s correlation and linear regression analysis.
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Chapter 1: Identification of a Novel Feed Forward Loop

24

Glycolytic Enzymes Regulate HIF-1α Activity
In order to identify genes potentially regulating cellular HIF activity we conducted a genomewide siRNA screen using MIA PaCa-2 pancreatic cancer cells with a stably integrated 5x
HRE/promoter-luciferase (luc) reporter to search for genes that, when silenced would inhibit HIF
activity. It is important to note that the reporter cannot distinguish between HIF-1 and HIF-2
activity which was made evident by results that will be discussed later. That screen, which was
conducted using a genome wide siRNA library (Dharmacon), identified several glycolysisrelated factors. This was an unexpected finding given that while it is known that expression of a
number of glycolysis genes are up-regulated by HIF-1

[4, 27]

, although not by HIF-2

[27]

, the fact

that glycolysis had any regulatory effect on HIF transcriptional activity had not been reported.
Identification of various genes in the pathway opened an interesting new avenue in an early
novel therapy design effort so the up-regulation of potential targets as a result of HIF-1 activity
was confirmed in MIA PaCa-2 cells using small scale, directed mRNA expression profiling. By
limiting a typical class discovery experiment in which thousands of possible gene expression
levels can be assessed

[78]

and analyzing only glycolytic genes, a clear pattern of reliance on

HIF-1 activity for expression during hypoxic stress was identified (Table 2).
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Gene:

Fold change hypoxia:

Fold change siHIF-1α:

HK1

2.611

0.491

HK2

5.308

0.426

HK3

No Change

No Change

GPI

2.108

0.675

PFKM

0.701

1.250

PFKL

No Change

No Change

PFKP

No Change

No Change

PFKFB1

No Change

No Change

PFKFB2

No Change

No Change

PFKFB3

No Change

No Change

PFKFB4

No Change

No Change

ALDOA

2.319

0.716

ALDOB

No Change

No Change

ALDOC

14.840

0.333

TPI1

2.299

0.533

GAPDH

2.051

0.658

PGK1

5.473

0.378

PGK2

7.947

0.259

PGAM1

2.287

0.649

PGAM2

No Change

No Change

BPGM

0.588

1.505

ENO1

2.351

0.573

ENO2

4.807

0.277

ENO3

1.115

1.750

PKLR

No Change

No Change

PKM2

1.892

0.855

Table 2. HIF-1 Knockdown Inhibits Genes Encoding Glycolytic Enzymes in Hypoxic MIA PaCa-2 Pancreatic
Cancer Cells.
Thirty genes encoding glycolytic enzyme isoforms were selected for validation and investigation based on results
from the genome-wide siRNA screen used to identify inhibitors of cellular HIF-1α activity. Through the use of
microarray methodologies, we measured fold-change in expression of glycolytic enzymes following control siRNA
transfection and exposure to hypoxia (siControl hypoxia/siControl normoxia) or fold-change following HIF-1α
knockdown (siHIF-1α hypoxia/siControl hypoxia).
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The combination of a clear pattern of HIF-1 activity inhibition with siRNA knockdown of glycolytic
gene expression as observed in the primary, genome-wide screen and the heavy reliance on
HIF-1 expression and activity for glycolysis gene expression suggested the existence of a
previously undescribed glycolysis/HIF-1 feed forward loop. To test this possibility we used an
isolated panel of siRNAs specific to 30 glycolysis genes and their isoforms (including pyruvate
dehydrogenase, which is responsible for post-glycolytic pyruvate modification in mitochondria)
and measured HRE-luciferase activity and cell viability in the same well. Using MIA PaCa-2
pancreatic cancer cells, we found compelling evidence that glycolytic enzyme activity is critical
for the normal functionality of HIF-1, further confirming the observations that we made following
the primary screen (Figure 6). Similar results were obtained using PANC-1 HRE-luc pancreatic,
MDA-MB-231 HRE-luc metastatic breast and HT-29 HRE-luc colon cancer cell lines which had
been stably transfected with the same HRE-luc reporter used for the MIA PaCa-2 cells in the
primary screen (Figures 7 - 9). Despite marked changes in HIF-1 activity in gene knockdown
events across many of the siRNAs included in the panel, cell growth inhibition was rarely more
than 25% except in the case of ALDOA knockdown. The decrease in normalized HRE-luc
activity (luciferase activity normalized to effects seen on cell viability to remove cell death or
growth inhibition as a possible false positive for inhibition of HIF-1 activity) in all lines followed
the same pattern as the greatest decrease was observed following ALDOA inhibition, followed
closely by knockdown of PGK1 (phosphoglycerate kinase 1) or its isoform PGK2
(phosphoglycerate kinase 2) depending on the cell line. It is for this reason that ALDOA was
selected for further development of novel, dual glycolysis/HIF inhibitors.
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Figure 6. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in MIA PaCa-2 HRE-luc Cells.
Thirty genes encoding glycolytic enzyme isoforms were selected for validation from a genome-wide siRNA screen for
inhibitors of cellular HIF-1 activity. HIF-1 activity was measured using MIA PaCa-2 pancreatic cancer cells stably
transfected with a constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and after
24 hr hypoxia (1% oxygen). Values were then normalized to cell viability in the same wells following aspiration of
viability reagent. Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as
controls. Bars represent S.D. of 3 studies.
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Figure 7. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in PANC-1 HRE-luc Cells.
Same panel of thirty genes encoding glycolytic enzyme isoforms selected for validation from a genome-wide siRNA
screen for inhibitors of cellular HIF-1 activity were used to validate effects as measured in the MIA PaCa-2 line used
for primary screening purposes. HIF-1 activity was measured using PANC-1 pancreatic cancer cells stably
transfected with a constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and after
24 hr hypoxia (1% oxygen). Values were then normalized to cell viability in the same wells following aspiration of
viability reagent. Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as
controls. Bars represent S.D. of 3 studies.

29

160.

Relative Signal (%)

120.

80.

0.

Cells Only
Scrambled Control
siHIF1a
siPLK1
siHK1
siHK2
siHK3
siGP1
siPFKFB1
siPFKFB2
siPFKFB3
siPFKFB4
siPFKL
siPFKM
siPFKP
siALDOA
siALDOB
siALDOC
siTPI1
siGAPDH
siPGK1
siPGK2
siPGAM1
siPGAM2
siBPGM
siENO1
siENO2
siENO3
siPKLR
siPKM2
siPDK1
siPDK2
siPDK3
siPDK4

40.

Figure 8. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in MDA-MB-231 HRE-luc Cells.
Same panel of thirty genes encoding glycolytic enzyme isoforms selected for validation from a genome-wide siRNA
screen for inhibitors of cellular HIF-1 activity were used to validate effects as measured in the MIA PaCa-2 line used
for primary screening purposes. HIF-1 activity was measured using MDA-MB-231 metastatic breast cancer cells
stably transfected with a constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and
after 24 hr hypoxia (1% oxygen). Values were then normalized to cell viability in the same wells following aspiration of
viability reagent. Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as
controls. Bars represent S.D. of 3 studies.
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Figure 9. Changes in Glycolytic Enzyme Expression Alters HIF-1 Activity in HT-29 HRE-luc Cells.
Same panel of thirty genes encoding glycolytic enzyme isoforms selected for validation from a genome-wide siRNA
screen for inhibitors of cellular HIF-1 activity were used to validate effects as measured in the MIA PaCa-2 line used
for primary screening purposes. HIF-1 activity was measured using HT-29 colon cancer cells stably transfected with a
constitutively expressed HRE-luciferase reporter 72 hr after siRNA reverse transfection and after 24 hr hypoxia (1%
oxygen). Values were then normalized to cell viability in the same wells following aspiration of viability reagent.
Scrambled non-targeting, HIF-1α, and PLK1 (polo like kinase-1 for toxicity) siRNAs served as controls. Bars
represent S.D. of 3 studies.
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Similar inhibitory effects were observed in the 786-0 renal adenocarcinoma cell line stably
transfected with the same HRE-luciferase promoter, suggesting that regulation of HIF activity is
not limited to HIF-1, as these cells express HIF-2 exclusively. Furthermore, differences with this
cell line provided additional insight into the fact that siRNA mediated knockdown of glycolytic
enzyme expression inhibits HIF-dependent HRE activity in these cells but not the constitutive
CMV-luciferase found in a paired cell line which we generated, suggesting that these enzymes
are indeed critical for cellular HIF activity rather than solely inhibiting general luciferase activity
in our endpoint assays (Figure 10).
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Figure 10. Glycolytic Enzyme Expression is Critical for Global HIF Activity
786-0 renal adenocarcinoma cells were used to demonstrate the effect of glycolytic enzyme knockdown on global HIF
activity since these cells express no HIF-1α; instead they express only HIF-2α. Additionally, a complimentary 786-0
line was generated with a constitutively active CMV-luciferase reporter and was used to show that siRNA mediated
silencing of glycolytic enzymes reduces luciferase activity in a HIF dependent manner rather than global luciferase
inhibition. Scrambled non-targeting and HIF-2α siRNAs served as controls.
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ALDOA knockdown also resulted in the greatest inhibition of cell proliferation amongst the
panel of selected hits from the global siRNA screen. Following identification of the initial hits
from the original, pooled library screen, a second siRNA manufacturer was identified (Qiagen)
and individual oligos for selected targets were ordered and tested. By selecting sequences from
a second manufacturer, the potential for siRNA off-target effects experienced in the primary
screen can be overcome by two mechanisms. First, the deconvolution of the original pooled
library which contained four sequences targeting a single gene in a single well can be screened
independently. Second, by using a sequence different than that found in the original pool, the
documented phenomenon of exogenous introduction of siRNA into a cell and subsequent
possible downregulation of the expression of a large subset of genes in a microRNA-like
manner

[79-81]

can be overcome. Since only short regions of sequence homology between the

siRNA and target sequences are required for this effect, a greater variety in the tested
sequences adds confidence during validation steps. Results from the primary screen were
validated in this way using all four cancer cell lines previously mentioned for ALDOA, PGK1 and
PGK2 with comparable results amongst the lines (Table 3).
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Median Relative Luciferase Units (HRE Luciferase/Viability)
Sequence
ID

Accession
Number

Gene ID

MIA PaCa-2
HRE

PANC-1
HRE

MDA-MB-231
HRE

HT-29
HRE

Oligo 1

NM_000034

ALDOA

24.41

33.07

26.70

79.85

Oligo 2

NM_000034

ALDOA

23.21

23.10

23.16

20.23

Oligo 3

NM_000034

ALDOA

22.54

22.32

22.94

21.42

Oligo 1

NM_000291

PGK1

50.78

38.40

25.68

30.59

Oligo 2

NM_000291

PGK1

43.60

30.83

26.01

44.54

Oligo 3

NM_000291

PGK1

53.25

49.33

39.59

30.04

Oligo 1

NM_138733

PGK2

92.98

64.60

49.88

56.49

Oligo 2

NM_138733

PGK2

17.49

16.81

15.34

18.71

Oligo 3

NM_138733

PGK2

34.88

21.55

13.55

23.63

Table 3. ALDOA Knockdown Shows Greatest Inhibition of HRE Activity in Secondary Validation
Using siRNA from a second manufacturer, individual oligos from the original pool are deconvoluted and screened
individually. As a result, Aldolase A was again confirmed to have the greatest effect on HRE luciferase activity
following siRNA knockdown.
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Dual transfection of siRNAs targeting PGK1 and PGK2 suggested overlapping activities as
the combined, double knockdown gave at least additive inhibition of HRE-luc activity, without
significant inhibition of cell proliferation (Figure 11). ALDOA and PGK1 or PGK2 knockdown
inhibited cellular glycolysis, as measured by Seahorse® technology, in all lines (Figure 12) and,
additionally, markedly decreased cellular ATP in hypoxic MIA PaCa-2 and PANC-1 cells (Figure
13). HIF-1 knockdown was included as a control and resulted in a similar decrease in ATP level,
as expected due to decreased overall glycolysis. The results suggested to us that the effects of
ALDOA and PGK1/2 on HIF-1 could be mediated by AMPK that is commonly activated in
response to elevated AMP when cell ATP levels are lowered [82, 83].
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Figure 11. Dual Transfections of siPGK1 and siPGK2 Suggest Redundant Function
The additive effect on HRE-luciferase inhibition in dual transfected samples suggests inhibition of both PGK1 and
PGK2 isoforms is needed to achieve significant levels of hindrance of HIF activity; further development of PGK
inhibitors would require dual action.
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Figure 12. siRNA Knockdown of Key Glycolytic Enzymes Inhibits Cellular Glycolysis
The rate of cellular glycolysis and glycolytic reserve (defined as excess glycolytic capacity following Oligomycinmediated inhibition of mitochondrial oxidative phosphorylation) was measured using Seahorse® technology, as
illustrated in the data key at left in all four of the HRE-luciferase lines used throughout various experiments in this
work (PANC-1 and MIA PaCa-2 pancreatic, MDA-MB-231 metastatic breast and HT-29 colon cancer lines).
Measurements were taken after reverse transfection with siRNA targeting ALDO isoforms A, B and C (either
separately or pooled), PGK1 and PGK2 (separately or pooled). Scrambled, non-targeting, and HIF-1α siRNAs served
as controls. Bars represent standard deviations from four biological replicates for each sample.
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Figure 13. siRNA Knockdown of Key Glycolytic Enzymes Inhibits Generation of ATP
Cellular ATP levels 72 hours after transfection with siRNA targeting HIF-1α, ALDOA, and PGK1 or 2 and 16 hours in
hypoxia. Bars represent standard deviation from three separate experiments.
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HIF-1α Activity is Mediated by AMPK Activation and EP300 Inactivation
We first established that, in all cells, decreased HIF-1 activity caused by ALDOA or PGK1 or
2 knockdown occurred without changes in HIF-1 protein levels and was qualitatively similar in
normoxia or hypoxia, although an overall greater effect was seen in hypoxia when HIF-1 levels
are elevated (Figure 14). To evaluate possible mechanisms underlying this activity we cotransfected glycolysis-related siRNAs with siRNAs targeting proteins that are known to regulate
HIF-1 activity;

[84, 85]

. We found that AMPK siRNA rescued the effects of ALDOA or PGK2

knockdown on HIF-1 inhibition, but observed little effect when glycolytic siRNAs were
transfected with p300 or PCAF siRNAs (Figure 15). FIH siRNA also reversed the effects of
ALDOA and PGK1 on HIF-1 activity, likely due to loss of negative regulation of HIF-1. Evidence
that the effect is mediated through AMPK regulated actions were further confirmed when the
effect of ALDOA or PGK1 or PGK2 knockdown was abolished following treatment with the
AMPK inhibitor dorsomorphin (Figure 16). Furthermore, western blotting showed that ALDOA
knockdown significantly increased phosphorylation of AMPK on Thr172, a marker of AMPK
activation in response to cellular stress such as ATP depletion

[86-89]

, in both normoxia and

hypoxia (Figure 17).
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Normoxia

Normoxia

Hypoxia

Hypoxia

Normoxia

Hypoxia

Normoxia

Hypoxia

Figure 14. Knockdown of ALDOA or PGK1 or 2 Inhibits HIF-1 Activity Without Decreasing HIF-1α Protein
Levels.
HIF activity was measured in air (Normoxia) or 1% O2 (Hypoxia) using four cancer cell lines of various types stably
transfected with the HRE-luciferase reporter 72 hr after transfection with siRNA targeting ALDOA or PGK1 or 2 and
after 24 hr in hypoxia. Bars represent S.D. HIF-1α protein was also measured by Western blotting. Scrambled, nontargeting, and HIF-1α siRNAs served as controls.
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Figure 15. Dual Transfections Suggest AMPK Responsible for Glycolytic Regulation of HIF Activity
Dual reverse transfection of siRNAs targeting ALDOA or PGK1 or 2 plus siAMPK (protein kinase, AMP-activated,
alpha 2 catalytic subunit), siEP300 (E1A-associated cellular p300 transcriptional co-activator protein), siPCAF
(p300/CBP-associated factor), and siFIH (Factor Inhibiting HIF-1). Results indicate that AMPK inhibition mediates the
effects of loss of ALDOA or PGK1 or 2 on HIF-1 activity.
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Figure 16. Inhibition of AMPK Activity by siRNA Knockdown or Treatment with AMPK Inhibitor Leads to HIF
Activity Recovery Following Glycolytic Enzyme Knockdown
HIF-1 activity following knockdown of ALDOA, PGK1, or PGK2 72 hr after transfection and after 24 hr in hypoxia
(filled boxes). Effects are rescued following treatment with the AMPK inhibitor dorsomorphin at 5 µM or with siRNA
targeting AMPK (open boxes). “*” indicate a p value less than .05 comparing siTarget to dual transfections of siTarget
and siAMPK; “ǂ” indicate a p value less than .05 comparing siTarget + DMSO treatment with siTarget + 5 micromolar
dorsomorphin treatment
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Figure 17. ALDOA Knockdown Results in Hyper Activation of AMPK
Western blot showing enhanced phosphorylation of AMPK (at Thr172 following silencing of ALDOA, or PGK1 or
PGK2 72 hours after siRNA transfection and after 24 hours in hypoxia in MDA-MB-231, HT-29, MIA PaCa-2 and
PANC-1 cells harboring the HRE-luciferase reporter.
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We next addressed how activation of AMPK (5'AMP protein kinase) by phosphorylation on
its activating loop at Thr172 in response to increased AMP, formed from ADP through adenylate
kinase

[90]

, could lead to inhibition of HIF-1 transcriptional activity. AMPK phosphorylates many

downstream substrates, one of which is p300/CREB binding protein (p300/CPB)
transcription factor necessary for HIF-1 transcriptional activity

[92]

[91]

a nuclear

. Unlike other phosphorylations

of p300/CPB, phosphorylation on Ser89 by AMPK specifically blocks its transcriptional activity
by interfering with its ability to act as a histone acetyltransferase [91]. Phosphorylation of p300 at
Ser89, which we observed following knockdown of ALDOA or PGK2 particularly in hypoxic
conditions, occurs following AMPK activation, attenuating the interaction of p300 with numerous
nuclear receptors in vitro and in vivo

[93]

(Figure 18). Thus the mechanism we are proposing for

the regulation of HIF-1 activity by glycolysis inhibitors is that, in response to lowered ATP,
AMPK is activated and phosphorylation of p300/CREB at Ser89 leads to its dissociation from
HIF-1 leading to decreased HIF-1 transcriptional activity.
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Figure 18. EP300 Phosphorylation Mediates AMPK Effects on HIF-1 Activity
Western blot showing enhanced phosphorylation of AMPK (at Thr172) and p300 (at Ser89) following silencing of
ALDOA, or PGK1 or PGK2 72 hours after siRNA transfection and after 24 hours in hypoxia in HT-29, MIA PaCa-2
and PANC-1 cells harboring the HRE-luciferase reporter.
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To investigate this further, EMSA analysis of MDA-MB-231 HRE luc cells with siRNA
mediated knockdown of ALDOA show a complete loss of HIF-1 binding to HRE sequences on
DNA. Dual transfection of both siALDOA and siAMPK result in a restoration of HIF-1 binding
(Figure 19). These results suggest that inhibition of glycolysis and a concomitant decrease in
HIF-1α activity are mediated by AMPK activation, possibly in response to low cellular ATP
levels, which in turn promotes p300 phosphorylation and terminates its ability to co-activate HIF1 transcriptional activity (Figure 20).
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Figure 19. siRNA Mediated Knockdown of ALDOA in MDA-MB-231 Cells Results in Loss of HIF-1 DNA
Binding Ability.

Electrophoretic Mobility Shift Assay showing complete loss of HIF-1 binding to HRE sequences following knockdown
of ALDOA. Binding ability is restored with coincidental knockdown of AMPK.
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Figure 20. Proposed Mechanism of Glycolytic Control of Cellular HIF-1 Activity
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Variable Expression of Aldolase Isoforms Suggest Compensatory Effects on Glycolysis
To further understand variable effects of ALDOA knockdown on proliferation amongst the four
HRE luciferase lines we next conducted immunoblotting to analyze expression of Aldolase B
and C isoforms in normoxia and hypoxia to uncover possible compensatory mechanisms when
ALDOA is eliminated. Interestingly, we found that the HT-29 HRE line, which shows only
minimal decreases in cell viability after ALDOA knockdown, exhibits significantly higher
expression of ALDOA compared to MDA-MB-231, MIA PaCa-2 and PANC-1 lines, which show
significant decreases in viability following ALDOA knockdown (Figure 21). Additionally, high
expression of ALDOC in the HT-29 line suggests a possible compensatory effect in the absence
of ALDOA at this step of glycolysis. Irregular expression patterns of ALDOA and PGK1 and
PGK2 proteins were confirmed by western blot analysis in 12 lung cancer cell lines (Figure 22).
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Figure 21. Aldolase Expression Level Correlates with Sensitivity to siRNA Mediated Knockdown
Cells expressing low levels of ALDOA are especially sensitive to siALDOA knockdown while cells expressing high
levels are less sensitive.
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Figure 22. Differential Expression of ALDO or PGK Isoforms in Cancer Cell Lines
The panel of cell lines used in Western blot analysis of PGK1, PGK2 and ALDOA was expanded to include cell lines
from various tumor types and stage. Densitometry analysis of western blots of lysates from these lines compares the
induction measured between normoxia and hypoxia treated samples.
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Inducible ALDOA knockdown Extends Median Survival in an in vivo Model of Metastatic
Breast Cancer
To validate ALDOA as a potential therapeutic target and because we have shown that ALDOA
knockdown is acutely toxic to cancer cells in vitro we expressed a doxycycline-inducible ALDOA
shRNA in MDA-MB-231 HRE-luciferase cells, and then used those cells to establish an
orthotopic model of metastatic breast cancer in female NOD-SCID mice. Two clonal lines
showing complete (clone 8.8) or partial (clone 9.7) ALDOA knockdown and glycolysis inhibition
following doxycycline treatment were used (Figure 23). Mice fed doxycycline either one week
before implantation of cells or when the primary tumor reached approximately 250 mm3 showed
increased median lifespan. Mice fed doxycycline a week before implantation showed increases
from 37 days in parental, and 41 days in empty vector transfected cells, to 50 and 56 days in
two clonal cells lines (p<0.001in both cases); mice treated once tumors were established
showed increases from 41 days (untreated) to 48 days (p < 0.001 compared to control) (Figure
24). Since the inducible shALDOA vectors were transduced into HRE-luciferase cells,
transdermal fluorescence imaging of the mice was made possible as a measure of HIF activity
in vivo. With this additional measure, we hypothesize that the extended life expectancy as a
result of shALDOA knockdown can be partly attributed to an inhibition of HIF activity since
luciferase readings in mice with sh8.8 showed significantly lower mean luciferase readings in
both pre-treated and doxycycline treated established tumors compared to tumors established
from the parental cell line (Figure 25). Postmortem analysis of mice indicated significant
metastasis from the primary tumor to the lungs and liver in tumors derived from parental lines
but not from tumors derived from the transduced clones.
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Figure 23. Inducible shALDOA MDA-MB-231 Breast Cancer Lines Established for Use in in vivo Studies.
Two lentiviral shALDOA doxycycline-inducible clones of MDA-MB-231 metastatic breast cancer cells were
established (clones 8.8 and 9.7). Both show doxycycline-inducible ALDOA knockdown together with inhibition of
glycolysis (as assessed using Seahorse® technology) and reduced HIF-1α activity, based on activity of the HREluciferase reporter measured under hypoxic conditions.
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Figure 24. Inducible ALDOA Knockdown in MDA-MB-231 Breast Cancer Tumors Extends Survival of
Xenografted Mice.
6

Groups of 5 immunodeficient SCID mice were injected in the breast fat pad with 1x10 MDA-MB-231 parental or
vector-only cells, or with clones 8.8 or 9.7. Animals received dietary doxycycline (625 mg/kg) starting 7 days before
3
injection of cells or when tumors reached approximately 250 mm . Death occurred in all cases associated with
metastasis of the MDA-MB-231 cells to the liver and lungs. Median survival of mice with parental MDA-MB-231
tumors was 37 days and with empty vector cells 41 days. Following doxycycline treatment mice injected with clone
8.8 or clone 9.7 cells 7 days before cell injection had a median survival of 56 days and 50 days, respectively (p<0.001
relative to combined controls groups in both cases). Animals receiving doxycycline treatment when the tumors
3
reached ~ 250 mm had a median survival of 41 and 48 days (p<0.001 compared to combined control groups in both
cases). At the time of death, lungs and liver of the mice showed extensive metastatic nodules.
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Figure 25. Inducible ALDOA Knockdown in MDA-MB-231 Breast Cancer Tumors Reduces HIF Activity in vivo
In vivo HIF-1α activity was determined using the MDA-MB-231 HRE-luc highly metastatic breast cancer cell line after
induced silencing of Aldolase A with shRNA. Mice (n=5/group) were measured with Xenogen IVIS imaging system
and intraperitoneal injection of luciferin starting 14 days after cell implantation. Silencing of Aldolase A resulted in
significant inhibition of HIF-1α activity either in subjects that received doxycycline before cell implantation (doxy pre
3
injection group) or after tumors had grown to 250 cubic millimeters (doxy @ 250 mm group). * P<0.01 for both
groups relative to non-transduced MDA-MB-231 HRE-luc cells receiving equal doxycycline treatment.
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Carrying murine xenograft data forward and in order to determine the clinical relevance and
therapeutic implication of novel Aldolase inhibitors for patients with a variety of tumor types, we
examined whether expression levels of various Aldolase isoforms correlated with any
measureable differences in overall patient survival. Aldolase A, B and C mRNA expression data
was obtained from the PANCAN dataset from The Cancer Genome Atlas (TCGA) (n = 9755).
Using the TCGA expression data, we found that elevated Aldolase A and C expression was
significantly correlated with poor prognosis in regards to survival rates (p < 0.0001 in both
cases) even when corrected for cancer type and patient age and sex (Figure 26). Alternatively,
no difference in PFS is observed between high and low level expression of Aldolase B (Figure
27), suggesting that A and C isoforms are more significantly associated with progression to
advanced disease states. Collectively, this data indicates that Aldolase isozymes are both
attractive targets for therapeutic intervention in cancer progression and could also serve as
critical diagnostic factors for determining patient response to therapy and overall prognosis.
ALDOA expression is clearly associated with poor clinical prognosis of a variety of cancer types,
suggesting that its expression patterns could be used in advance to select patients in which
Aldolase inhibition would be both beneficial and critical for overall patient health.
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Figure 26. The Cancer Genome Atlas Data Suggests Aldolase A and C Isoform Expression Data Predicts
Overall Patient Survival
Comparison of tumor and paired normal tissue samples from 9755 patients for ALDOA and ALDOC mRNA suggests
high expression of either in patient tumors could be predictor of poor prognosis. Survival data is corrected for tumor
type, patient age and patient sex.
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Figure 27. The Cancer Genome Atlas Data Suggests Aldolase B Isoform Expression Data Cannot be Used as
a Predictor of Overall Patient Survival
Comparison of tumor and paired normal tissue samples from 9755 patients for ALDOB mRNA suggests high
expression of the protein in patient tumors has little to no predictive value. Survival data is corrected for tumor type,
patient age and patient sex.
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Considering the differential expression of ALDOA in cell lines and the correlative
pattern that we observed in regards to sensitivity to its knockdown, we next analyzed
available TCGA expression data and found, upon initial analysis, that elevated Aldolase
A expression was significantly correlated with lower median survival in a variety of
cancer types pointing to its potential value as a prognostic factor in the treatment of
such diseases with novel inhibitors currently under development (Figure 28).
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Figure 28. Variable Expression of ALDOA in Tumors Predicts Median Survival
Initial consideration of TCGA data following cell line analyses shows a pattern of poor prognosis with high ALDOA
expression relative to paired normal tissue.
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Discussion:
HIF-1α is a key transcription factor that functions in cell survival in stressful hypoxic
environments established by many solid tumors due to poor vascularization. Amongst these
targets are pro-angiogenic genes such as PDGF and VEGF
accelerated tumor cell proliferation such as MYC

[95, 96]

[23, 26, 28, 94]

, genes associated with

, and genes functioning in migration,

invasion and remodeling of the extracellular matrix and contributing to increased cell survival
and heightened metastatic potential

[97-99]

. HIF-1 promotes cell survival by up-regulating genes

related to cancer cell metabolism and rapid production of ATP and glycolytic metabolites
100]

[4, 29,

. Increased HIF-1α signaling is observed in many pathophysiological conditions, including

pancreatic, colon and breast cancers. However, inhibitors designed to disrupt HIF-1’s protective
role have thus far been largely ineffective. Thus we took an unbiased approach by utilizing a
high-throughput siRNA screen to identify factors that mediate HIF-1α transcriptional activity, in
part to reveal novel targets for HIF-1α inhibition. Unexpectedly, several hits in the screen were
enzymes functioning in glycolysis.

While it was previously known that HIF-1 increases the

glycolytic rate in tumors by inducing expression of glycolytic enzymes
previously been reported that glycolysis increases HIF-1 activity.

[4, 5, 27, 29, 100]

, it has not

We found that 16 of 30

glycolytic enzymes and isoforms were associated with some inhibition of HIF-1 transcriptional
activity. Among them, ALDOA and PGK 1/2 knockdown resulted in robust inhibition of HIF-1
activity in all lines tested.
Cellular protein synthesis is energetically expensive; thus protein synthesis rates are tightly
regulated in order to couple nutrient availability to signals driving proliferation. It is known that in
an energy crisis when glycolysis is inhibited, ATP levels decrease and AMPK is activated
subsequently leading to mTOR mediated decreased expression of HIF-1 protein

[101]

. However,

under hypoxic conditions, as found in solid tumors, decreased degradation of HIF-1, at least in
the short term, increases levels of HIF-1 protein, which paradoxically obscure potential
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decreases in translation. However, we now report that HIF-1 protein is not transcriptionally
active when glycolysis is inhibited. The EP300 co-activator is required for numerous signaling
pathways governing cellular proliferation and differentiation, processes tightly controlled by p300
phosphorylation status

[102]

. Specifically, p300 phosphorylation at serine 89 following AMPK

activation dramatically reduces p300 interaction in vitro and in vivo with numerous nuclear
receptors but does not alter interaction with non-nuclear receptors

[93]

. We confirmed these

findings in glycolysis inhibition following knockdown of ALDOA, or PGK1 and PGK2, suggesting
that control of the transcriptional machinery by activated AMPK is achieved through disruption of
normal cancer cell metabolism. Thus, in response to lowered cellular ATP levels, AMPK is
activated and p300 phosphorylation at Ser89 promotes dissociation from HIF-1α, decreasing its
transcriptional activity.
Interestingly, HIF-2α activity is also subject to inhibition when glycolysis is inhibited as we
observed in the case of the 786-O renal line. HIF-1 and HIF-2 upregulate both common and
unique downstream targets, and HIF-2 does not upregulate glycolysis genes as does HIF-1.
Thus, we conclude that HIF-2 does not participate in the feed forward loop described here, but
rather its activity is dependent on HIF-1 stimulation of glycolysis. Most cancer cells express
HIF-1 under acute hypoxic conditions, but in prolonged hypoxia HIF-2 is expressed and HIF-1
levels fall

[46]

. The consequences of HIF-2 inhibition need to be investigated, particularly in clear

cell renal cancer cells, which predominantly express HIF-2.
Here we show that ALDOA and PGK1/2 isoforms are the most critical of 40 isoenzymes of the
glycolytic pathway in terms of maintenance of normal HIF-1α activity, making both attractive
targets to inhibit both cancer cell energy metabolism and survival of stress. The marked
extension in median survival time of mice with ALDOA knockdown in the MDA-MB-231 model of
metastatic breast cancer confirms this point and opens the possibility of novel drug screening
and therapeutic options for cancer subtypes linked to HIF-1α and ALDOA expression.
Furthermore, identification of ALDOA as a potential novel regulator of HIF-1 could be clinically
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relevant, since ALDOA expression levels are reportedly significantly elevated relative to other
glycolytic enzymes in several human tumor types

[57, 103]

, providing a novel means to inhibit HIF-

1α function in several solid tumors. Variable expression of Aldolase isoforms in the panel of 4
HRE luciferase lines used here suggests a compensatory mechanism for ALDOC in the
absence of ALDOA. In particular, high ALDOC levels seen in HT-29 HRE cells could explain
why ALDOA knockdown had minimal impact on this line and demonstrate a need for therapeutic
agents targeting both ALDOA and ALDOC. Variability in the pattern of Aldolase isoform
expression was further confirmed in a panel of 12 lung cancer cell lines (Figure 23). Currently,
there are no clinically available inhibitors of these critical steps in glycolysis; establishment of
agents targeting crucial components of the pathway could be useful to treat cancers that survive
using these mechanisms.
Malignant transformation reportedly shifts cells to a pattern of glycolytic enzyme expression
that favors uncontrolled proliferation and facilitates energy production and metabolite production
in an oxygen free setting

[104, 105]

A feed forward loop in tumors promoting increased HIF-1

activity and increased glycolysis provides a target to block tumor energy production pathways
and the HIF-1α survival response. Our activity-oriented RNAi screen and subsequent
mechanism-based analysis expands our understanding of known and novel regulators of the
HIF-1α transcription factor and suggest previously uncharacterized regulation of HIF-1 activity
by glycolytic enzyme expression. Moving forward, by designing a therapeutic intervention for
ALDOA activity, we hope to inhibit both cancer cell metabolism and the tumor cell’s ability to
survive hypoxic stress thus exploiting a dual Achilles’ heel of the cancer cell.
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Chapter 2: Designing a Chemical Probe
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Virtual High Throughput Screening Quickly Characterizes Potential Lead Compounds
In the realm of rational drug design, molecular docking programs are frequently used to
predict the binding orientation of small molecule pharmacological probe candidates to targets of
interest in the form of proteins or, more specifically, enzymes in order to predict the affinity that
the small molecule has for the active site of that target

[106]

. In this way, the use of recursive

docking programs in screening operations can play a critically important role in the rational
design of new pharmaceutical agents. Given the biological and pharmaceutical potential of
these molecular docking systems, considerable efforts have been directed towards the design
of new methods and tools that can be used to predict docking [106].
Taking into account the availability of small molecule data bases, these screening
methodologies can be focused on drug-like molecules that are either commercially available for
testing in biological assays or can be easily generated from already available materials or
processes. In this way, the characterization of available chemical compounds, natural products
and drugs can be accomplished in such a way as to gain an understanding as to what basic
structures stand to give the greatest effect against the target of choice and manipulated later for
SAR based studies [107].
GOLD (Genetic Optimization for Ligand Docking) is a program for calculating the likelihood
of certain docking conformations of small molecules in specifically outlined protein binding sites
as determined by the program’s user

[108]

. The automated ligand docking program uses a

genetic algorithm to explore the full range of possible ligand conformations within a specified
binding site with partial flexibility of the protein at that site, and satisfies the requirement that the
ligand of interest displaces loosely bound water on binding. The software package consists of
several programs; the first, for visualization and manipulation of the unadulterated protein
structure as input from the protein databank, a second for the calculation based protein-ligand
docking screening algorithm and a third for post-processing and visualization of the docking
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results from high-throughput virtual screening.

An extensive review of literature outlining

information regarding both the crystal structure of the Aldolase A isozyme and studies of the
effect of mutation of specific residues on the functionality of the enzyme yielded a set of six
critical residues to be included in the specifically outlined protein flexibility algorithm: Asp33,
Ser38, Lys146, Arg148, Glu187, and Lys229. The program, by including protein side chain and
backbone flexibility in this user defined list of residues within the protein of interest, takes into
account the wide range of possible conformations of not only individual substrates but also the
enzyme itself during the virtual docking mechanisms. The results of the survey of the literature
were visualized and manipulated in PyMOL, a molecular visualization system capable of
translating Protein Data Bank files into high quality 3D images [109] (Figure 29).
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Figure 29: Computer model of active binding site of Aldolase A isozyme
Using the published available crystal structure for Aldolase A (4ALD in PDB), PyMOL was used to visualize the
surface of the active binding site of the enzyme (orange) to contrast the cartoon version of the enzyme as a whole
(teal) and Fructose-1,6-bis(phosphate), the enzyme’s natural substrate (shown in dark blue). Using this method, key
residues in the binding site were identified for virtual screening methodologies.
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Virtual High Throughput Sigma TimTec Myria Screen Uncovers Novel Tool Compounds
For the purposes of this study, GoldScore, the original scoring function within a range of
possible criteria sets for assessment of ligand binding, was selected as it has been optimized for
the prediction of ligand binding positions and takes into account factors such as H-bonding
energy, van der Waals forces and strain on the ligand itself given specific conformational
changes

[110]

. Additional features that made this scoring function ideally suited for this particular

project were alluded to earlier, as GoldScore is the only scoring function that takes into account
flexible residues within the targeted binding site - in cases where program users are docking a
ligand into a binding site known to contain a flexible side chain (such as the Aldolase isozymes),
it is possible to specify that these residues be allowed to undergo automatic rotation around one
or more of its acyclic bonds. Since it was determined from literature review that there were at
least six critical residues that were capable of torsional rotation, this was the clear choice for
appropriate scoring functions

[111-113]

. In this way, the conformations of the flexible motifs were

altered during docking in order to optimize the hydrogen bonding interactions of the residue with
the ligand, improving the final indication of likelihood of binding affinity.
Using the solved crystal structure (4ALD from Protein Data Bank) and the parameters as
outlined above, the Sigma TimTec Myria library of 10,000 compounds was selected for initial
screening.

The value of this library was the careful consideration of several physical and

chemical properties by the library’s designers at both Sigma and TimTec including the diversity
of molecular weight, cLogP (measure of relative hydrophobicity), hydrogen bond acceptors,
hydrogen bond donors, and rotatable bonds. Further, the collection is largely drug like according
to Lipinski’s Rule of 5

[114]

which was useful for this screening operation in that we were

interested in identifying novel inhibitors that could be made into pharmacological probes for
further drug design efforts.

Each of the 10,000 compounds was docked in five possible
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conformations in order to yield a range of scores for each compound taking into account several
possible docking scenarios within the active site.
If the system were perfect, the calculated binding energy of a specific substrate would
correlate perfectly with an experimental binding energy, so that the pose with the lowest
predicted binding free energy would correspond directly to the experimentally determined
structure. Since the process of free energy calculation is confounded by many factors
surrounding the interaction between the substrate and specific residues within the binding site,
this is not always the case; for this reason, it is often found that the lowest energy structure
predicted by docking will not be the closest to the experimentally determined crystal structure of
the protein. Molecular docking processes are generally used to simply identify a set of
compounds to be used in further development experiments rather than to select a single
compound on which to base all future research. Taking this into account, it was important to
include a system of checks and balances in the original experimental design in order to
measure the effectiveness of residue selection.

As a validation of the effectiveness of the

screening procedure, fructose 1,6-bisphosphate was included with the Myria compound library
to be included in the list of possible compounds; this natural substrate ranked among the top ten
compounds according to its binding affinity relative to the compounds found in the screened
library initially verifying the validity of residue selection for use during the screen.
Upon completion of the screening operation that considered over 50,000 possible
permutations of potential small molecule inhibitors and their binding to the active site of ALDOA,
GOLD fitness was used as a parameter to describe the interaction between the ligand and the
binding site.

In order to further refine the selection process, several parameters were

considered:

1. The number of times that each of the five iterations of each compound’s
conformational changes appear amongst the top ranked hits was taken into account.
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Logically, a compound that appeared four times in top 20 compounds was more
likely a worthwhile hit than one that only appears once in the top 100.
2. Compounds were removed from the list if the cLogP was over 2 since this would
neither be easy to test in cell models, nor a useful therapeutic agent if in vitro work
proved the agent was effective at silencing the action of Aldolase A.
3. For the most part, chemicals that were symmetrical were taken out of the ranks;
however, there was one compound in the top ten that consistently ranked highly
according to its GOLD score that was not removed.
4. The diversity of chemical structures was also considered in the selection process
since the likelihood that even after early in vitro work each of the chosen structures
would have to be modified for purposes of SAR studies at a later time was
considerable.

After cropping the list of top hits from 50,000 to just 100, the top hits were then rescreened
in GOLD with 20 iterations of possible conformations using a fully flexible binding site model.
As expected, this process did not have a significant effect on the ranking of each compound.
Finally, these top 100 compounds were visually inspected in PyMOL relative to the natural
substrate to make sure that there were not significant changes in the structure of the docked
complex relative to the proven crystal structure. This also was effective in showing how each of
the potential probes fit into the binding site relative to critical residues and the natural substrate
itself. During this procedure the list of 100 compounds was again reduced to the top 22 which
were chosen for in vitro experiments. Since Aldolase is found at a critical point in glycolysis in
which NADH is oxidized, a simple spectrophotometric assay was employed for this function.
Optimization experiments to determine the ideal concentration of Aldolase protein for use per
well in a 96 well plate format gave proof that the assay was robust enough for testing of
inhibitors from the virtual screen (Figure 30).
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Figure 30. Optimization of NADH Oxidation Mediated Aldolase Activity Assay
Initial work in the development of a multi-well plate assay to measure the activity of ALDOA has used a 96 well plate
assay based on conversion of fructose 1,6-bisphosphate (F-1,6-BP) into glyceraldehyde 3-phosphate (GAP) and
dihydroxyacetone phosphate (DHAP) measured in a coupled reaction with GAP dehydrogenase by the oxidation of
NADH to NAD at 364 nm.. This reaction can be easily manipulated by altering initial ALDOA protein concentration in
the reaction well to produce changes in the velocity of the reaction which are proportional to the amount of active
ALDOA added.
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Of the tested compounds, 3-hydroxy-5-(4-isopropylphenyl)-1-(1,3,4-thiadiazol-2-yl)-4-(2thienylcarbonyl)-1,5-dihydro-2H-pyrrol-2-one (referred to as “Compound 6” due to its rank as the
6th best hit from the GOLD screen) gave the best results in the biochemical assay; however, the
non- Michaelis-Menten nature of the kinetic profile made the calculation of critical values used in
the description of an agents effect on enzymatic activity impossible. In order to understand
these effects on enzyme function, a kinetic description of their activity as measured as the rate
of catalysis of the natural substrate (described as the rate of product formation) is needed and,
typically, will vary proportionally with the concentration of the substrate – similar to the profile
seen in Figure 4. In this case, however, a lag phase in which inhibitory effects of the compound
are basically absent is observed prior to an immediate drop off (Figure 31).
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OD
Figure 31. Non-Michaelis-Menten Enzyme Kinetics Observed Using ‘Compound 6’
They typical hyperbolic plot that is found in Michaelis-Menten kinetics is missing with the use of Compound 6 in
recombinant protein based biochemical assessment of the proposed Aldolase A inhibitor. The 5 minute lag phase
followed by abrupt loss of Aldolase activity defies traditional enzymatic activity patterns and raises questions
regarding its activity as an Aldolase inhibitor.
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High Throughput Small Molecule Screen in vitro Uncovers Novel Pharmacological
Probes
Previous work suggests a modification of residues on the C-terminal tail of Aldolase which is
known to overlay the catalytic site might be responsible for inhibition of activity of the enzyme
[115]

. Since residues in the portion of the target were not considered in the initial GOLD screen, it

is possible that the results, while initially interesting, did not provide the robust effects that were
expected and inclusion of these residues in future screening efforts would be needed.
Considering the effectiveness of the biochemical assay used for the initial assessment of
hits from the virtual screen, large scale, high-throughput screening of small molecule libraries
using the assay was a logical next step. Typical assessment of Aldolase activity in vitro was
achieved through the use of a coupled enzymatic reaction with α-Glycerophosphate
Dehydrogenase (GAPDH). Since this step of glycolysis causes the conversion of NADH to NAD
in the presence of the natural products of Aldolase, the absorbance based quantification of
remaining NADH in solution could indirectly measure Aldolase activity

[70]

. However, since the

sensitivity of NADH absorbance is low, and since interference of small molecules with
absorbance less than the 400 nm wavelength required for the assay could result in high rates of
false positive identification, an alternative, first of kind, fluorescent based assay was developed
by medicinal chemists at the University of Texas at Austin (Ashwini Devkota, Eun Jeong Cho
and Kevin Dalby) in order to swiftly identify lead compounds for therapeutic development of
Aldolase A inhibitors (Figure 4, 5). The Elite NADH assay, which is marketed as a method to
measure the levels of NADH/NAD+ in various sample types, was repurposed for use in a highly
sensitive, high throughput function. The kit’s enzyme reduces a chromophore into a highly
fluorescent product in states of NADH dehydrogenation. Glyceraldehyde-3-phosphate
dehydrogenase converts glyceraldehyde-3-phosphate (G-3-P) to 1,3-bisphosphoglycerate (1,3BGP) through oxidative phosphorylation. NAD+ is oxidized to NADH when a phosphate group is
exchanged for a hydrogen on the carbonyl carbon of G-3-P thus converting G-3-P to 1,3-BGP.
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This

assay

uses

glycerophosphate

dehydrogenase

to

catalyze

the

conversion

of

dihydroxyacetone phosphate (the product of the ALDOA catalyzed reaction) to glyceraldehyde-3
phosphate in an NADH-dependent manner. Thus, the rate of change of fluorescence intensity
is used to indirectly calculate the activity of ALDOA. After identifying and manipulating this
system to fit our needs, robustness and reproducibility of the assay was validated through the
use of Z’-factor calculation in the comparison of positive control (all assay components in the
absence of ALDOA corresponding to complete enzymatic activity inhibition and, therefore,
highest fluorescence intensity) and negative control (all assay components in the presence of
excess ALDOA corresponding to full enzymatic activity of Aldolase and, therefore, lowest
fluorescence intensity) wells in the presence of an optimized concentration of Aldolase A
recombinant protein (Figure 32) and Fructose-1,6-bisphosphate substrate (Figure 33) per well.
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Figure 32. Assay Optimization: Enzyme Dose Response Versus Time
Preliminary optimization experiments included the identification of appropriate Aldolase A concentration per well – 0,
5, 10, and 20 nM recombinant protein were evaluated against standard concentrations of substrate and reaction
mixture (including glyceraldehyde dehydrogenase). With a reaction completion time of ~30 minutes, 5 nM Aldolase
was chosen for use in further optimization experiments.
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Figure 33. Assay Optimization: Substrate Concentration
Following the optimization of Aldolase A concentration per well, F(1,6)BP concentration was optimized against 5 nM
protein and standard NADH and GDH per well. Falling in the linear range of the kinetic profile generated during this
optimization, 100 µm F(1,6)BP was chosen for the finalized assay parameters.
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Using this assay, characterization of over 65,000 chemical agents obtained from both
commercial and academic suppliers was made possible while limiting the likelihood of false
positives due to interference caused by absorbance inherent to the small molecules alone.
Similar to the Myria screen used for virtual screening methods described earlier, collections of
these agents which were selected for functional screening were compiled based on structural
diversity amongst available biologically active known drugs or natural products and hits were
selected based on the criteria of 25% inhibition of Aldolase activity following the execution of the
assay.

Discussion
By using an unbiased, large scale, small molecule library screen in a recombinant protein
assay, the typical challenges associated with cell based small molecule screens can be
overcome. While many of the compounds found in these libraries have either undetermined
targets or have been previously identified as inhibitors of proteins other than those that we are
trying to exploit in this study, early results suggest a promising panel of pharmacological probes
for the inhibition of normal Aldolase function. Despite this fact, there are a wide range of cellular
functions, components of the extracellular space and physiological confounders that can hinder
the clear efficacy that we observed in the initial screen and further work both in vitro and in vivo
is required.
By carrying ‘hit’ compounds into cell based assays a number of parameters could be
satisfied in an ongoing attempt to design an effective therapy for the ubiquitous processes
associated with tumor cell metabolism and stress survival. First, identification of compounds
which are effective in both biochemical and cell based in vitro experiments can provide novel
insight about differences between cell types and, in the case of normoxic versus hypoxic cells,
the inherent variability between different cellular states. Second, after identifying molecules that
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are most effective in the cell based assays, new compounds can be designed and generated for
use in SAR studies in order to optimize analogues with molecular structures that, although
similar, may have a greater efficacy in target inhibition. And third, the eventual FDA approval of
any compound will be almost impossible without a clear understanding of its cellular target and
the effect that it has in order to achieve its inhibition even if the effect on cancer cell death, HIF
activity, and energetics is profound.
While initial findings from our large scale small molecule screen were promising, the
understanding that physiological components can act as hindrances to a compound’s efficacy
highlight the need to optimize the pharmacokinetic and pharmacodynamic parameters of our
early lead compounds.

Delivery of an active compound to the target after escape from

vasculature, penetration into tumor cells which are distal to the convoluted vasculature of a
tumor and maintenance of its biologically active form after traveling throughout the body are all
considerations to be made and overcome in the steps following initial identification of a
promising hit compound.
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Chapter 3: Developing a Novel ALDOA Inhibitor
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Identification of Lead Compound for Testing Based on Time Dependent Inhibition of
ALDOA in Biochemical Assay
In order to confirm that ALDOA is a target with potential for cancer therapy we sought to test
small molecule probes initially identified as inhibitors of recombinant human ALDOA first in the
chemical library screen in cell based, biological assays. Identified in the biochemical assay,
amongst other compounds, was TDZD-8, a previously described, selective, non-ATP
competitive GSK-3β inhibitor

[116]

. In this initial screening assay, this compound showed a time

dependent inhibition of protein function suggesting a direct interaction with the ALDO protein
used in the assay (Figure 34). Pointing again to the value and flexibility of small molecule library
screening, we felt that the identification of a compound with previously described use in cancer
as an inhibitor of a target other than ALDOA could have value later on in the drug development
process if proof of this protein interaction could be realized. To that end, a combination of in
vitro and in vivo experiments investigating this interaction and the effect that it had on cancer
cells and subsequent xenograft tumors was initiated.
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Figure 34. Time Dependent Inhibition of ALDOA Function Suggests Direct Protein Binding
The small molecule TDZD-8 was discovered as an inhibitor of recombinant human ALDOA activity through a
chemical library high throughput screen. Varying concentrations of TDZD-8 were either pre-incubated for 30 minutes
with recombinant ALDOA or introduced into assay wells at the initiation of the enzymatic assay. In this way, inhibition
of ALDOA was shown to be time dependent suggesting that TDZD-8 could be interacting directly with the protein.
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X-ray Crystallography Implies Cysteine Residues Distal to Active Site are Critical for
Normal ALDO Function
To address the matter of TDZD-8 interaction with the ALDOA protein, X-ray crystallography
studies were initiated in which ALDOA crystals were soaked with the inhibitor to measure
residues which might be responsible for the inhibitory effects that we observed in the primary
screen. Human ALDOA is found as a tetramer

[68, 117]

, and our X-ray crystallographic studies

showed that TDZD-8 bound with full occupancy to Cys289 in each of the four ALDOA subunits
of the tetramer, and with partial occupancy at Cys239. Both Cys residues are on the surface of
the tetramer and distal to the catalytic site (Figure 35), so their mechanism of inhibition is
currently unclear.

Interestingly, the literature survey that lead up to virtual high throughput

screening methodologies used at the start of this drug discovery effort did not include residues
outside of the substrate binding site; that said, the results from this study came as a surprise.
The reaction of 1,2,4-thiadiazoles with the Cys sulfur leads to opening of the thiadiazole ring
between the nitrogen and sulfur and formation of an irreversible disulfide bond. This is a
relatively slow reaction that is dependent on the nucleophilicity of the cysteine sulfur

[118]

, which

may account for the slow reaction in the ALDOA inhibition studies that we observed previously
(Figure 34). The S-S bond may also be stabilized by a hydrogen bond between the carbonyl
oxygen at the 3-position in the ring, designated as the “recognition arm”

[119]

and an H-bond

donor in the protein. The electron density is fully consistent with disulfide bond formation and
ring-opening. It is significant that there was marked loss of inhibition by TDZD-8 when ALDOA
Cys289 was mutated to Ala further implicating this residue in inhibitory effect of the agent on
ALDOA functionality.
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Figure 35. Cys239 and Cys289 Binding Appear Critical for Inhibition of ALDOA Function
Human recombinant ALDOA crystals were soaked with TDZD-8 and refined at 2.5 Å resolution to an R-factor of 20%
(RFREE = 24%). The crystal structure showing TDZD-8 (blue and red stick structure) bound specifically to Cys-289 of
each monomer in the tetrameric ALDOA complex; and to a much lesser extent to Cys-239. The electron density
supports the formation of an S-S bond between protein and inhibitor and concomitant breaking of the S-N bond within
the 1,2,4-thiadiazole ring. In general, density for the terminal Phe group is weak or non-existent, consistent with its
flexibility. There is no evidence for modification of any other Cys residues. Both modified Cys residues are located
distal to the catalytic pocket of ALDOA, (shown by a black and red stick structure of a partial substrate analog) and
their mechanism of ALDOA inhibition is currently unclear. It is noteworthy that TDZD-8 bound better to ALDOA
crystals when they were co-crystallized (i.e., prebound) with the substrate analog.
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Assessment of Glycolytic Substrates, Intermediates, and Products Suggests Aldolase
Inhibition
The YSI 7100 Multiparameter Bioanalytical System Analyzer allows for focused analysis of
specific metabolites in biological samples. To measure a substrate of interest, one or more
enzymes are immobilized between two membrane layers in the instrument’s sensor. YSI
membranes contain three layers. The first layer limits the diffusion of the specific substrate into
the enzyme layer and prevents the reaction from becoming enzyme-limited. The third layer
excludes nearly all electrochemical compounds from interfering with the measurement of
hydrogen peroxide as the endpoint product. Using this robust system, the swift quantification of
various substrates, intermediates, and products of the glycolytic process can be carried out. In
addition to the XTT and luciferase assays used to show its inhibition of cancer cell proliferation
and HIF-1 activity (Figure 36) and the reduction in ECAR observed when using the Seahorse
BioScience® XF96e platform that is consistent with glycolysis inhibition, we were also able to
show that TDZD-8 inhibited glycolytic activity at low µM concentrations by quantifying the ratio
of lactate and glucose using the YSI platform (Figure 37). Lastly, GC-MS technology was
employed for metabolic flux analysis using stable isotope labeling in which the absolute
quantities

of

critical

intermediates

were

assessed.

Most

notably

affected

were

dihydroxyacetone phosphate (DHAP) and pyruvate suggesting that Aldolase was being inhibited
following treatment with TDZD-8 (Figure 38). Despite not seeing overall inhibition of glycolysis
(i.e. relatively constant levels of 3PG, PEP and lactate) we suspect that the inhibitor is still
having an overall negative effect on the cell’s ability to conduct glycolysis and that this is only a
reflection of intracellular pool sizes of specific glycolytic intermediates, especially considering
the significant reduction in DHAP concentration per sample following treatment.
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Figure 36. TDZD-8 Inhibits Cancer Cell Proliferation and HIF-1 Activity in vitro
Panel showing in vitro TDZD-8 inhibition at low micromolar IC50 concentrations of cellular HIF-1 activity (as
measured with the HRE luciferase reporter) and cancer cell proliferation.
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Figure 37. TDZD-8 Inhibits Glycolytic Activity in vitro
Panel showing in vitro TDZD-8 inhibition at low micromolar IC50 concentrations of cellular glycolytic activity as a
function of both the Extra Cellular Acidification Rate (ECAR) as measured by Seahorse® Technology and the ratio of
lactate to glucose in the medium as measured by YSI technology.
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Figure 38. GC/MS Analysis Shows TDZD-8 Inhibition of Glycolysis in vitro
GC-MS analysis of cell lysates after 6 hours of treatment with TDZD-8 (20 µM) of MDA-MB-231 cells shows a
reduction of DHAP, the direct product of Aldolase, and pyruvate suggesting an inhibition of cellular glycolysis. Amino
acids whose levels are not known to be affected by glycolysis were included as assay controls.
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TDZD-8 Inhibits Tumor Growth and Glycolysis in vivo
Although TDZD-8 is a reactive molecule, our results support a significant level of specificity
and we used it as a pharmacological probe to see if we could inhibit ALDOA in vivo and solicit
an antitumor effect. When administered intraperitoneally daily for 20 days at a dose of 12
mg/kg/day to mice with MDA-MB-231 orthotopic breast cancer tumors, TDZD-8 caused
significant slowing of tumor growth by about 60% by day 32. Pharmacokinetic studies showed
no detectable parent compound in the mouse plasma, but pharmacodynamic studies after a
single dose of TDZD-8 showed about a 50% decrease in tumor lactate levels within 4 h, a 40%
decrease in dihydroxyacetone phosphate (a product of the cleavage of fructose-1,6bisphosphate by ALDOA), and a slower decrease over a period of days in downstream
phosphoenolpyruvate (Figure 38). Thus, TDZD-8 itself at low levels or an active metabolite
appears to reach the tumor to inhibit tumor glycolysis and is associated with measureable
antitumor activity.
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Figure 39. TDZD-8 Inhibits Tumor Growth and Glycolysis in vivo
TDZD-8 at daily doses of 12 mg/kg by intraperitoneal injection daily for 20 days to immunodeficient SCID mice with
MDA-MB-231 tumor xenografts shows significant inhibition of tumor growth. There were 10 mice per group and bars
3
are S.E. of the mean. * p = < 0.05 and ** p = <0.01 compared to control mice. MDA-MB-231 xenografts (~ 250 mm )
were also collected at 1 and 4 hr after a single intraperitoneal dose of TDZD-8 of 12 mg/kg, or 4 hr after the last of 5
daily doses (Q5D + 4), and tumor levels of lactic acid, dihydroxyacetone phosphate (DHAP) and 3 phosphoglycerate
were measured. Values are the mean of 4 mice each and bars are S.E. * p = < 0.05 compared to non-treated control
tumors.
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Discussion
We initially identified a link between glycolytic gene expression and HIF-1 as a promising
target with potential for development of selective inhibitors of both cancer energetics and stress
survival. Of the key enzymes found in the glycolytic pathway that came out as interesting genes
in the primary screen, ALDOA was selected as a gene that had a high level of selectivity for the
inhibition of global HIF activity in the cell and a drug discovery effort was initiated in order to
identify novel pharmacological probes of the enzyme. Combining both virtual and biochemical
based high throughput screening methodologies, a putative small molecule inhibitor was
identified and found to be effective in the inhibition of glycolysis, HIF activity and cell viability.
Measurement of extracellular flux and the corresponding ECAR by Seahorse ® technology
was used as a proxy for lactate production was a key first glimpse into TDZD-8’s activity as a
potent inhibitor of both the basal and maximal glycolytic rates in cancer cells. Taking the
analysis of glycolysis inhibition a step further, GC/MS was employed to investigate the effect
that TDZD-8 treatment had on pool sizes of key glycolytic intermediates (like DHAP, the main
product of Aldolase activity) relative to untreated cells and found evidence that the small
molecule inhibitor was indeed interfering with cellular glycolytic function.
Much like the effects that were observed in siRNA mediated functional genomics studies
putative small molecule inhibitors identified in the high throughput screen were also tested for
their ability to inhibit cell viability and global HIF activity. The combination of the XTT viability
assay and in-house HRE luciferase activity was again used to identify inhibitors of these key
cellular processes and, as suspected based on the profound level of glycolysis inhibition
observed in a range of assays, TDZD-8 was identified as a key inhibitor; these results confirmed
the findings discussed previously regarding the interplay between Aldolase and normal HIF
function and, through validation of the findings in a panel of cell lines, this small molecule was
selected as a useful tool compound for future studies.
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Finally, the validation of the overall findings in each of the in vitro experiments mentioned
above was carried forward into the same murine model used for shALDOA studies mentioned
earlier. Intraperitoneal administration of TDZD-8 into these mice had the clear effect of
recapitulating the anti-tumor activity of ALDOA knockdown by induced shRNA with the added
evidence of 3PG, DHAP and lactate production inhibition following GC/MS analysis.
Taken together, these findings suggest that the careful design of high throughput screening
methodologies through the use of either virtual or in vitro platforms followed by selection of
promising inhibitors identified using these assays has yielded a promising small molecule
inhibitor of cancer cell metabolism, stress survival mechanisms, and ultimately tumor
development and progression.
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Chapter 4: Summary and Future Directions
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Solid tumors present researchers with a very unique set of hurdles during the drug
development process which must be encountered and navigated when considering the specific
needs in the design of a targeted therapy. Normal glycolytic function is a critical means for
tumors to generate much needed energy in the form of ATP for the development of new
biomass as the rapidly dividing cells found within the tumor microenvironment expand

[5, 120]

.

Because of this rapid expansion of the cells which form them, solid tumors typically outgrow a
normal vasculature and, therefore, possess poorly organized blood vessels that are often
described as having erratic and chaotic branching structures

[121]

. This results in the possible

separation from functional blood vessels and, subsequently, a hypoxic environment which is
inherently stressful to normal cells while heavily favoring tumor growth

[21-23]

. Unlike normal

cells, a cancer cell’s ability to survive the stress associated with a hypoxic environment is
ultimately attributed to the expression of the hypoxia inducible transcription factors HIF-1 and 2
[24, 25]

and the cascade of enhanced expression of a range of survival genes which are

associated with their activity. Because of their critical functions, both have been extensively
studied as possible therapeutic targets as means to inhibit tumor growth and cancer cell survival
[7, 56, 60, 92, 122-125]

. Although many attempts have been made to identify HIF specific inhibitors

through a variety of mechanisms (inhibition of HIF-1 protein synthesis
the transactivation of HIF target genes

[128]

[126]

and stabilization

and even its translocation into the nucleus

[129]

[127]

,

), drug

development attempts in this realm have ultimately fallen short. Through the execution of this
work we are now able to report that because of the previously unknown feed forward
relationship between glycolysis and HIF activity as a transcription factor, we have uncovered a
novel target for the inhibition of tumor growth.

Future Directions: Glycolytic Regulation of HIF Activity
While the finding that there is a clear relationship between ALDOA inhibition and the
reduction in cellular glycolysis and HIF activity is an interesting one, there are additional
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experiments that could be conducted in order to further solidify the proposed mechanism of this
regulation and further understand the molecular basis for this regulation.
First, in Chapter 1 I outline the fact that AMPK activation following ALDOA knockdown leads
to the phosphorylation of the p300/CREB binding protein [91]. The subsequent deactivation of its
transcriptional activity can be attributed to the loss of HIF function without the loss of HIF protein
expression, a result which we saw in a number of cell lines. As a possible confirmatory study,
site directed mutagenesis could be employed to investigate the relationship between p300
phosphorylation and the ALDOA/HIF feed forward loop. Since we argue here that
phosphorylation at Ser89 is a critical step in the dissociation of HIF and its critical co-activator,
mutation of this key residue and overexpression in various cell lines would confirm this finding
following knockdown of glycolytic enzymes as previously described.

Following ALDOA

inhibition using this model, Ser89 mutation should result in a rescue of HIF activity in the cell
and could be measured using a number of the assays described here including HRE-luciferase
activity and loss of HIF binding in the EMSA assay.
Second, although we see very little effect of glycolytic enzyme knockdown in cancer cells
following treatment with normoxic conditions, it would be interesting to investigate the effects
with both siRNA mediated and putative small molecule inhibitor mediated inhibition of ALDOA
activity in normal cells.

That said, through the use of available cell lines such as mouse

embryonic fibroblasts (3T3) or immortalized human fibroblasts, for instance, the effect of
ALDOA inhibition could be further investigated as a means to selectively disrupt cancer cell
proliferation while also generating only minimal toxicity in otherwise normal cells and minimal
side effects compared to traditional therapies in patients. We assume that because of the
profound differences between cancer and normal cell metabolic pathways of choice that the use
of normoxic cancer cells in these assays would be proof enough that this kind of novel therapy
would avoid such toxicity to healthy tissue but the presence of additional genetic confounders
between the cell populations may warrant additional consideration.
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Future Directions: TDZD-8 and Analogs’ Mechanism of Action
In chapter 3, the effects of siRNA mediated ALDOA deletion were recapitulated with a small
molecule inhibitor identified from a high throughput in vitro small molecule screen with clear
effects on the inhibition of cellular glycolysis and HIF function as well as antitumor activity in
mice.
Despite this fact, the experiments with TDZD-8 do not necessarily point to a clear inhibition
of ALDOA activity in vivo. As noted, TDZD-8 was initially marketed as a GSK-3β inhibitor [116] so
a clear demonstration of ALDOA inhibition in tumors may be critical. In order to accomplish this,
it would be interesting to again employ site directed mutagenesis studies at the two key cysteine
residues mentioned previously (Cys239 and Cys289). Generation of Cys289Ala mutants and
the more conservative mutant, Cys289Ser, for comparison will allow for multifaceted follow-up
work; while the substitution of cysteine by alanine would offer a non-polar alternative thus
eliminating the possible interaction with TDZD-8, the serine substitution and possible
participation of this residue in hydrogen bonding would be preserved. Establishing cell lines
which express these mutated proteins will provide the tools to carry out several forms of
confirmatory studies. First, the in vitro treatment of several cell lines harboring these mutant
ALDOA proteins with TDZD-8 will provide an early assessment of the drug’s activity as it
specifically relates to this suspected critical residue. Additionally, the broader applicability of the
inhibitor in tumors could be established by using several cell lines both with and without the
ALDOA mutations by painting a more complete picture using orthotopic models with other
cancer cell lines.
Carrying this exciting new inhibitor forward, SAR studies with analogs could provide
additional insight into its mechanism of action and possible ways to improve the efficacy. This
will also require these agents to acceptable pharmacokinetic and pharmacodynamic properties
thus requiring additional modifications to this tool compound’s structure. Should these initial
challenges be overcome, however, the inhibition of Aldolase activity could emerge as an
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exciting novel therapeutic option for patients without the typical side effects associated with
traditional chemotherapeutic agents.

Summary
The overarching goal for modern translational research efforts is the design of new agents
and therapeutic strategies for the inhibition of cancer specific targets in order to spare healthy
tissue and avoid toxicities associated with a lower quality of life for patients undergoing
treatment.

Despite years of ongoing research surrounding gene and protein expression

similarities and differences between cancers and normal tissue, the wide range of targets and
the heterogeneity found from one individual to the next has confounded even the best attempts
at new inhibitors and therapies. As I have discussed here, the use of high throughput screening
methodologies in carefully designed assays has led to the identification of a novel interplay
between cancer cell metabolism and the transcriptional activity of the hypoxia inducible factor
and, as a result, a new therapeutic target has been identified. With a new small molecule
inhibitor currently in preclinical investigation, the value of the combination of basic research,
computational biology, chemistry and pharmaceutical design found within an experimental
therapeutics program is clear. The collective knowledge from each of these realms contributed
to the development of a novel tool compound with great potential for an eventual impactful
clinical therapy.
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